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 Prostate cancer is the most common malignant cancer and the second leading 
cause of cancer-related death among men in the United States. The major aim of this 
dissertation was to develop stimuli-responsive, targeted therapeutics for prostate cancer 
treatment.  
 In the first part, 2-[3-(1,3-dicarboxypropyl)-ureido] pentanedioic acid (DUPA)- 
targeted N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-docetaxel (DTX) 
conjugates were developed for treatment of prostate cancer expressing prostate-specific 
membrane antigen. The in vivo results show that the spacer length between targeting 
moieties (DUPA) and HPMA copolymer backbone can significantly affect the treatment 
efficacy of DTX conjugates against C4-2 tumor bearing nu/nu mice.   
 In the second part, a tumor-homing peptide iRGD and histone deacetylase 
inhibitor valproic acid conjugate (VPA-GFLG-iRGD) was developed and its activities 
were tested against prostate cancer cells. The  conjugate  VPA-­GFLG-­iRGD  and  a  mixture  
of  valproic   acid   (VPA)   and  GFLG-­iRGD  have   shown  similar   cytotoxicity   against  DU-­
145  prostate  cancer  cells.  However,  the  treatment  of  DU-­145  cells  with  conjugate  VPA-­
GFLG-­iRGD   resulted   in   a   decreased   percentage   of   cells   in   the  G2   phase,  whereas   the  
exposure  of  a  mixture  of  VPA  and  GFLG-­iRGD  led  to  an  increased  percentage  of  cells  in  
the  G2  phase.  
  
iv 
 In the third part, tumor-homing and penetrating peptide iRGD-targeted HPMA 
copolymer doxorubicin conjugates (P-DOX-PLGLAG-iRGD) were developed for 
prostate cancer treatment. iRGD was attached to HPMA backbone via a matrix 
metallopeptidase 2 (MMP-2) cleavable spacer (-PLGLAG-). Doxorubicin (DOX) was 
conjugated to HPMA copolymer via a lysosomal cleavable tetrapeptide spacer (-GFLG-). 
The activities of P-DOX-PLGLAG-iRGD and related controls were assessed in both 
monolayer and multilayer prostate cancer cells. The results demonstrated that the 
conjugate P-DOX-PLGAGL-iRGD has better penetration ability than P-DOX and a 
mixture of P-DOX and iRGD.  
 In the fourth part, a HPMA copolymer CXCR-4 antagonist (BKT140) conjugate 
(P-PLGLAG-BKT140) was developed for inhibiting prostate cancer cell migration. 
BKT140 was attached to the HPMA backbone via a matrix metallopeptidase 2 (MMP-2) 
cleavable spacer (-PLGLAG-). The in vitro cell cytotoxicity results show that the 
conjugation of BKT140 to HPMA did not impact the functionality of BKT140. The 
migration results show that both HPMA copolymer BKT140 conjugate and free BKT140 
inhibited the CXCL12 induced PC-3 prostate cancer cell migration. The conjugate P-
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1.1 Prostate Cancer 
Cancer accounts for 25% of the total deaths in the United States, making it the 
second leading cause of death (1). Prostate cancer is the most common diagnosed (except 
for skin cancer) and the second leading fatal cancer among men in the United States. The 
American Cancer Society estimated that about 233,000 men will be diagnosed with 
prostate cancer and about 29,480 Americans will die from this disease in 2014 (1). 
 
1.2 Prostate Cancer Origin 
As shown in Figure 1.1, the prostate epithelium consists of three differentiated 
cell types: luminal, basal, and neuroendocrine (2?4). The argument about prostate cancer 
cellular origins is still in controversy (5). Cell biologists assume that basal cells are the 
origin of prostate cancer because they have a more regenerative potential than luminal 
cells in normal prostate (5). However, most pathologists consider that prostate cancer 
originates from luminal cells because prostate tumor tissue consists of epithelial luminal 
cells and lacks epithelial basal cells (6). The difficulty in identification of the origin of 
prostate cancer is partly due to the fact that the prostate epithelial lineage hierarchy has 










Figure 1.1: Schematic depiction of the cell types in human prostatic duct. 











are the origin of prostate cancer (2). However, Witte and colleagues claim that basal cells 
are the origin of human prostate cancer (8). They further demonstrated that advanced 
prostate adenocarcinoma initiated in basal cells can be maintained by luminal-like tumor-
propagating cells (9). Apparently, ????????????????????????????????????????????her, but in 
fact, the Shen group used cells that were from an adult mouse prostate, but the Witte 
group used human prostate cells. Recent research found that both prostate basal and 
luminal cells can serve as the cellular origin of prostate cancer using a lineage tracing 
approach (7).  
 
1.3 Prostate Cancer Stages and Treatment 
 As shown in Figure 1.2, prostate cancer progression can be divided into four 
stages: clinically localized disease, biochemical recurrence, castration resistant non-
metastatic disease, and castration resistant metastatic disease (10). The first stage of 
prostate cancer (localized) can be treated with surgery and radiotherapy. The second and 
third stage of prostate cancer can be treated with androgen ablation (10). Finally, a small 
portion of prostate cancer develops to fatal, metastatic castration-resistant prostate cancer 
(CRPC). Although chemotherapeutic compounds (paclitaxel, docetaxel, doxorubicin, 
radium-223 dichloride) have been developed to treat CRPC, they can only provide 
medium overall survival improvement (11,12).  
 
1.4 Physiologic Difference Between Normal and Tumor Tissues 
In normal tissue, the blood vessels are well organized and most of the ? 1013 cells 











Figure 1.2: Clinical stages of prostate cancer and current therapeutic 










proliferate faster than normal cells, thus the uncontrolled proliferating tumor cells 
compress and collapse the intratumor vessels (14). The basement membrane, endothelial 
cells, and pericytes in tumor vessels are disorganized and irregularly shaped. These cells 
are loosely connected, or overlapped or sprouted (15,16). The composition, assembly, 
and architecture of tumor vascular basement membrane are changed. Compared to 
normal vessels, tumor vessels are leaky, tortuous, and dilated, with uneven diameter, 
excessive branching, and shunts (17). The poorly organized, irregular blood vessels block 
the delivery of nutrients, oxygen, and anticancer drug to the tumor area. Furthermore, the 
rapidly proliferating cancer cells force vessels apart and create a population of cells 
distant (> 100 ?m) from blood vessels (13,18).   
 ????????????????????????????????????????????????????????llaries are absent from the 
interior, but they are enlarged in the periphery of a solid tumor (17,19). One possible 
explanation is that the lack of pulsatile blood flow may inhibit the growth of lymph 
system (14). Perhaps the stress, which is produced by the rapidly proliferating tumor cells, 
prevents the formation of a functional lymphatic system (14,17,20). The enlarged 
lymphatics in tumor periphery may be due to the overexpression of vascular endothelial 
growth factor (VEGF-C) (21).  
The abnormal structure and function of blood and lymphatic vessels in prostate 
cancer result in the formation of a prostate cancer microenvironment. The accumulation 
of lactic acid and CO2 results in a low extracellular pH because the irregular tumor 
vasculature is insufficient to remove lactic acid and CO2 (22). The blood-vessel leakiness, 
lymph-vessel abnormalities, and contraction of interstitial space most likely contributes 
to the elevated tumor interstitial fluid pressure (IFP) (23,24).  
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1.5 Prostate Cancer Microenvironment 
 As in other cancers, the prostate cancer microenvironment is also a complex 
milieu. This chapter only discusses hypoxia, matrix metalloproteinases (MMPs), prostate- 
specific antigen (PSA), prostate-specific membrane antigen (PSMA), and chemokines. 
MMPs will be discussed in Section 1.5.1. Prostate cancer unique markers including 
prostate-specific antigen and prostate-specific membrane antigen will be discussed in 
Section 1.5.2. The chemokines, which control both the growth of primary and metastatic 
tumor (25,26), will be discussed in Section 1.8.  
Similar as in other tumors, hypoxia regions also exist in mouse, rat xenografted 
prostate tumors, and human prostate carcinoma (27?29). The hypoxia level is associated 
with prostate cancer clinical stage (30). Gerald and coworkers reported that oxygen 
tension in prostate cancer tissue (average media pO2, 2.4 mmHg) is much lower than the 
normal tissue (muscle, average media pO2, 30.0 mmHg) (31). Hypoxia-related genes, 
lysyl oxidase and glucose transporter-1 are highly expressed in prostate cancer tissue 
compared to benign prostatic hypertrophy (BPH) tissue (32). Immuno-histochemical 
analysis of 289 prostate cancer patients indicated increased expression of hypoxia marker 
HIF-1 alpha after surgery (33). The hypoxia microenvironment induces the high 
expression of CXCR4 receptor on prostate cancer cells and more stem-like tumor cells in 
prostate tumor (34,35). Hypoxia microenvironment in prostate cancer results in increased 






1.5.1 Prostate cancer microenvironment-MMPs 
The MMPs are a family of zinc containing endopeptidases, and they play a critical 
role in the regulation of tumor invasion and metastasis (34,35).  All the known 26 human 
MMPs contain four domains: N-terminal pro-peptide domain, catalytic domain, hinge 
region, and hemopexin-like C-terminal domain (39,40). Based on their specificity, MMPs 
are divided into four subgroups: collagenases, gelatinases, stromelysins, and matrilysins 
(40). The activity of MMPs is inhibited specifically and reversibly by natural tissue 
inhibitors of metalloproteinases (TIMPs) (38). The imbalance activity between MMPs 
and TIMPs causes pathological disorders (40).  
Matrix metalloproteinases-2 (MMP-2), a type IV collagenase, is one of the 
important MMPs in drug delivery. The 2.8 Å resolution X-ray crystal structure of 
proMMP-2 has been analyzed and solved by Tryggvason and coworkers in 1999 (41). As 
shown in Figure 1.3, proMMP-2 consists of four domains: pro-domain (red), catalytic 
domain (blue), fibronectin domains (green) and hemopexin domain (yellow) (41). The 
pro-domain is a three-helix globular domain (41). The catalytic site of pro-MMP2 
comprises a five-stranded ?????????????????????????????????Zn2+ ions, and two Ca2+ ions 
(41). The fibronectin domain contains ????????????and ???????????? (41). The hemopexin 
domain is composed of four blade propeller folds (41). 
MMP-2 overexpression is associated with many cancers, including prostate 
cancer (42,43). In normal tissue, the function of MMP-2 is to degrade extracellular matrix. 
As other MMPs, inhibitors of matrix metalloproteinases-2 (TIMP-2) co-exist with MMP-
2. In benign prostate, the ratio of MMP-2/TIMP-2 is about one, while this ratio can 








Figure 1.3: Structure of proMMP-2. The pro-domain, catalytic domain, fibronectin 
domains, and hemopexin domain are shown in red, blue, green, and yellow, respectively. 








the MMP2 gene increased with prostate cancer progression (43). MMP-2 is highly 
expressed in prostate cancer, but low in prostate hyperplasia (44). Immunohistochemical 
analysis of the prostate cancer tissue showed that MMP-2 expression percent in prostate 
cancer patients was 85.5% (53/62), while the percent was 6.7% (1/15) in BPH tissue. The 
MMP-9 expression in prostate cancer and BPH patients were 80.7% (50/62) and 13.3% 
(2/15), respectively (45). Enzyme-linked immunosorbent assay (ELISA) analysis of the 
active MMP-2 protein in cell culture media of PC-3 and LNCaP showed a concentration 
of about 2000 pg/mL, while the active MMP-2 concentration in normal prostatic 
epithelial cells culture media was only about 700 pg/mL (46). The MMP-2 protein 
concentration in plasma from PCa patients with metastasis was also higher than that of 
patients with BPH and healthy volunteers (47).  
 
1.5.2 Prostate cancer markers PSA and PSMA 
Prostate-specific antigen (PSA) is a 33 kDa glycoprotein secreted by the prostatic 
epithelium and the epithelial lining of the periurethral glands (48). PSA is a widely used 
marker for prostate cancer detection, but the controversy is increasing because PSA 
screening resulted in both false-positive and false-negative results (49). 
PSMA was detected in 33/35 of primary prostate adenocarcinomas, 7/8 lymph 
node metastases, and 8/18 bone metastases after immunohistochemical analysis of 
malignant human tissue from patients with prostate cancer (50). PSMA enzyme activity 
in prostate cancer samples was about 10-fold higher than that in BPH and normal tissue 
(51). Based on the data from 136 cases of prostate cancer, PSMA expression is strongly 
related to the serum PSA level: the mean serum prostate-specific antigen in PSMA  
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overexpressing group was 18.28 ng/ml, while the mean serum PSA in non-PSMA-
overexpressing group was 9.10 ng/mL. Taken together, those data implied that PSMA is 
an important maker for prostate cancer diagnosis and treatment (52). 
PSMA is a Mr 100,000 type II membrane protein containing a 19-amino acid (aa) 
cytoplasmic fragment, a single 24-aa membrane-spanning fragment, and a 707-aa 
extracellular region (53,54). PSMA exists as a noncovalent homodimer on the prostate 
cancer cell surface, and requires dimerization to maintain its functions (54). As shown in 
Figure 1.4.A, the 3.5 Å crystal structure of the extracellular region of PSMA consists of 
three domains: a protease domain (residues 56-116 and 352-591); an apical domain 
(residues 117-351); and a helical domain (residues 592-750) (55).  
As shown in Figure 1.4.B, the active site of PSMA is located at the interface 
between the three domains. A water molecule bridges two zinc ions, which are 
coordinated by three endogenous ligands: a histidine, a terminal aspartate or glutamate, 
and a bridging aspartate (55). 
 
1.6 Drug Targeting to Solid Tumor 
One of the major reasons for the low efficacy and high toxicity of systemically 
administered drugs is due to low accumulation in the tumor area (usually less than 5% ID) 
(56). The low drug accumulation in the tumor is due to two major reasons: first, the 
dysfunctional blood vasculature fails to deliver enough drug to the tumor area; second, 
the high interstitial pressure in the tumor area retards the extravasation of drug from 
blood vasculature to the tumor area. ?????????????????????????????has the potential to 











Figure 1.4: Structure of PSMA. (A) Ribbon diagrams of side views of PSMA; (B) 
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accumulation of drugs in tumor stroma and internalization in tumor cells (57). 
 
1.6.1 Passive targeting 
The passive targeting, also called Enhanced Permeability and Retention (EPR), 
effect was first discovered by Maeda?? group in 1986 (58,59). The EPR concept takes 
advantage of the irregular blood and lymphatic vessels in the tumor area (60?62). First, 
leaky vasculatures allow the enhanced extravasation of nanomedicines from the 
circulation system into the tumor. This reduces the undesirable side effect of 
nanomedicines. Second, the disfunctional lymphatic system in the tumor decreases the 
clearance of nanomedicines, thus enhancing retention time in tumor (57). Theoretically, 
nanomedicines can extravasate into the tumor through the leaky vessel by diffusion and 
convection, but the high interstitial pressure in the tumor reduces the driving force for 
convective movement. Thus, the extravasation of nanomedicines mainly relies on 
diffusion, that is, movement from a region of high concentration to a region of low 
concentration. This process is extremely slow. The passive delivery efficiency relies on 
the inherent physicochemical properties of nanomedicines (size, shape, charge, etc.) and 
pathophysiological features of the tumor.  
 
1.6.2 Active targeting 
The active targeting strategy is to decorate the surface of a nano-carrier with 
targeting moieties for binding to the overexpressing specific receptors on tumor cells. 
The original attempt for active targeting is to enhance the accumulation of a 
intravenously administered drug or imaging agent in solid tumors and lower systemic 
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exposure by a specific interaction between the targeting moieties and the receptors that 
are overexpressed or up-regulated on tumor vessels or cells (63). However, the higher 
binding affinity between ligands and receptors on cancer cells can only enhance the 
internalization of drug but not alter the accumulation of drug in tumor area (64,65). That 
is due to the fact that targeting moieties have no chance to interact with tumor cells until 
they reach the tumor (64). Despite this, active targeting still has the potential to provide 
safer and more effective anticancer treatment (66). Once nanomedicines arrive at the 
tumor, the ligand-receptor interaction can not only increase the retention time in tumor 
but also facilitate the uptake process (67). Currently, there are thirteen ligand-targeted 
nanomedicines in clinical trials (68). The active targeting strategies can be divided into 
two areas: (i) targeting cancer cells; (ii) targeting the tumor endothelial cells. The most 
popularly studied cancer cell receptors include: (1) transferrin receptor, (2) endothelial 
growth factors (EGF) receptor, (3) folate receptor. The two most studied tumor 
endothelium receptors are vascular endothelial growth factors receptors (VEGFR) and 
???3 integrin (69). Most of the nanomedicine is to block the interaction between vascular 
endothelial growth factors (VEGF) and VEGFR; this is beyond the scope of this 
dissertation (69)??????????3 integrin will be discussed in this chapter. 
Transferrin receptor (TfR) is the most pertinent target for active cancer treatment 
in the clinic, four of the thirteen targeted nanomedicines in clinical trials (MBP-426, 
SGT-53, SGT-94, and CALAA-01) target transferrin receptors (68). TfR is a 180 kDa, 
type II transmembrane glycoprotein, which contains an intracellular domain (61aa), a 
transmembrane domain (28aa), and a large extracellular domain (671aa) (70). Transferrin 
receptor is highly expressed on cancer cells with a density of 10,000-100,000 molecules 
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per cancer cell, while undetectable in normal cells (71). Because transferrin is up-
regulated in various types of cancer, it is possible that one targeting ligand-drug 
conjugate can simultaneously treat multiple cancers (72). The transferrin-targeted and 
nontargeted siRNA nanoparticles have similar biodistribution in a mouse tumor model, 
but the siRNA activity for transferrin-targeted nanoparticles is about 50% higher than that 
of nontargeted nanoparticles (65). The coating of transferrin on gold nanoparticles did not 
influence their biodistribution in tumor, but significantly increased the localization of 
nanoparticles in tumor cells (66). 
Epidermal Growth Factor Receptor (EGFR) is another attractive target. Two 
EGFR targeted nanomedicines are in clinical trial (68). EGFR is frequently expressed in 
various types of cancer (73). The anti-EGFR antibody can enhance the internalization of 
nanoparticles in pancreatic cancer cells (74). The coating of anti-EGFR peptide GE11 on 
the surface of nanoparticles increased the biodistribution about 2-fold in a subcutaneous 
human pancreatic adenocarcinoma mouse model (75). The GE11 assisted delivery of 
sodium iodide symporter gene resulted in the specific therapy of liver cancer (76,77). The 
coating of anti-EGFR antibody on poly(lactic-co-glycolic acid) (PLGA) nanoparticles 
enhanced their uptake in breast cancer cells (73).  
Folate receptor, a 38 kDa glycosyl-phosphatidylinositol-anchored glycoprotein, is 
overexpressed in a variety of solid tumors, including ovary, lung, breast, kidney, brain, 
endometrium, and colon cancer (67,69,78,79). Folate-targeted liposomes, micelles, and 
dendrimers have been studied for cancer treatment in mouse tumor models. The 
cytotoxicity of doxorubicin in folate-targeted liposomes was about 85 times greater than 
that in nontargeted liposomes (80). The heparin-folate-paclitaxel nanoparticles enhanced 
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the therapeutic efficacy of paclitaxel (81). A folate-targeted micelle containing 
doxorubicin prevented breast cancer metastasis compared to that of nontargeted micelles 
(82). Folate decorated poly(amidoamine) (PAMAM) dendrimers were able to deliver 
siRNA for cancer treatment (83).  
The expression of integrin is associated with cancer growth and progression (84).  
?????????? ????? ?????? ??????????? ???3 integrin is overexpressed in both tumor and 
angiogenic endothelial cells (85). The tripeptide Arg-Gly-Asp (RGD), which was first 
discovered by Ruoslahti and coworkers, has high binding affinity toward integrins, 
especially ???3 (86). Now, the linear and cyclic derivatives of RGD containing peptides 
are commonly used for ???3 integrin-targeted drug and/or imaging agent delivery (84). 
The conjugation of CDCRGDCFC (RGD-4C) to doxorubicin significantly enhanced the 
efficacy of doxorubicin against MDA-MB-435 human breast cancer xenografts in nude 
mice and reduced the systemic toxicity of doxorubicin (87). RGD-targeted nano-
medicines have shown 15-fold enhancement in treatment of pancreatic cancer metastasis 
(88). Inhibiting the angiogenesis in tumor blood vessels by RGD-targeted gene therapy 
suppressed primary and metastatic tumor growth (89). ACDCRGDCFC was conjugated 
to cationic polymer (PEI) to assist delivery of gene for inhibiting angiogenesis and tumor 
growth (90,91). The attachment of RGD targeting moieties on HPMA copolymer drug 
conjugates significantly increased the accumulation of drug in prostate cancer tumor (92?
95). The conjugation of cRGD to zwitterionic near-infrared (NIR) fluorophore improved 





1.7 Drug Penetration and Cell-Penetrating Peptides 
 Although passive and active targeting can enhance drug accumulation in the 
tumor area and drug internalization in tumor cells, the drugs still need the ability to 
penetrate into the tumor interior to achieve efficacy (97). Some of the patients with 
CRPC benefit from chemotherapy, but some still die of prostate cancer because of the 
drug resistance (98). Resistance to chemotherapy treatment resulted from poor or limited 
drug distribution in solid tumors (63,99,100). Tannock and coworkers investigated the 
Doxorubicin (DOX) distribution in relation to tumor blood vessels in mice bearing PC-3 
tumor. As shown in Figure 1.5, most of the DOX distributed around the tumor vessels 
and did not reach hypoxic areas (101). The Minchinton group investigated the Taxanes 
penetration by measuring the drug effect in HCT-116 tumor xenografts (99). The drug 
effect at 150 ?m away from the vasculature was only about 70% of that in the tissue near 
the tumor vessels. In order to improve the accumulation of therapeutics in tumor area and 
increase the contact chance of interior tumor cells to drugs, researchers have developed 
cell-penetrating peptides (CPPs) to improve the penetration of drug into the solid tumor.   
 
1.7.1 Receptor-independent CPP 
 The concept of CPP ???????????????????????????????????????? group discovery 
in 1988 (102,103). They found that the TAT protein from human immunodeficiency virus 
1 (HIV-1) could be taken up by cells growing in tissue culture (102). The exact amino 
acid sequence (RKKRRQRRR), often referred to as Tat49-57 or the Tat 9-mer, that is 
responsible for the cellular uptake was first discovered by Lebleu and coworkers (104). 





















endocytic pathway and was not energy dependent (104). The application of TAT for 
delivery of macromolecules to cells started in ???????? ?????. They found that TAT 
fused 120-kDa b-galactosidase can be delivered to each tissue in mice after being injected 
intraperitoneally (105). Their findings overturned the concept that only small molecules 
can enter into cells (106).  
More CPPs were created through biomimetic or organic synthesis after the 
discovery of TAT. Some representative CPPs and relating sequences are shown in Table 
1.1. The discovery ??? ??enetratin? is based on the research that the third helix of 
homodomain of the Antennapedia is internalized by cells (107,108). Transportan is a 
combination of the first 13-amino acids in N-terminus of the galanin and the first 14-
amino acid in the C-terminus of mastoparan (109).  VP-22 is derived from Herpesvirus 
structural protein (110). Xentry is derived from a N-terminal region of the X-protein of 
the hepatitis B virus (111). Recently, Anderson group developed a set of 50 cell 
penetrating peptides derived from 46 proteins that can associate with the plasma 
membrane (112). Organic synthesis also helped to find new CPPs by mimicking arginine 
or lysine-rich CPPs (113). Norbornene-based guanidine-rich polymers were developed to 
mimic CPPs (114). Peptoid analogues containing a six methylene spacer between the 
guanidine head group and backbone are better than Tat49-57 in penetration application 
(115). Although there are hydrophobic CPPs (116) and amphipathic CPPs (117), most of 
the CPPs can be classified into guanidinium group-rich CPPs. For the guanidinium-rich 
peptides, the internalization is controlled by the number and order of guanidinium groups 





























The internalization of CPPs into cells can be divided into two steps. The first step 
is the association interaction between CPPs and cell membrane. The most accepted 
mechanism is shown in Figure 1.6. The guanidinium group can form a bidentate 
hydrogen bond with anionic cell surface phosphates, carboxylates, and/or sulfates to 
initiate cellular entry but not the ammonium group in cationic CPPs (118,120,121). The 
stoichiometry of peptide-heparan sulfate binding impacts the uptake efficiency of cell 
penetrating peptide (122).  
The second step is the CPPs cellular uptake. Although many researchers try to 
explain the cellular uptake mechanism of CPP, the mechanism is still not fully 
understood. Two general uptake mechanisms were generally considered: 1) Energy-
independent uptake directly across biological membranes (124); 2) Energy-dependent 
endocytosis. As shown in Figure 1.7, the endocytosis can be subdivided into four 
different pathways: macropinocytosis, clathrin-dependent endocytosis, caveolae/lipid 
raft-mediated endocytosis, and clathrin/caveolae-independent endocytosis. The cellular 
uptake mechanism of CPPs can be impacted by many factors: CPP type, attached cargo 
nature, cell types, or incubation condition. For example, the association of serum proteins 
in cell culture media with CPPs changes the cell uptake pathway (126,127)?? ????????
group found that Tat and Pentratin simultaneously used three endocytosis pathways to 
pass through cell membrane (128). 
One of the most important applications of CPPs is to overcome drug resistance 
(129). The conjugation of octa-arginine to taxol through a disulfide spacer can overcome 








Figure 1.6: Proposed association mechanism between CPP and cell membrane. 





















Figure 1.7: Possible cell penetrating peptide cellular uptake pathway.  
Adapted from reference (125). 
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toward breast cancer cells compared to free methotrexate because the CPP helps to 
overcome drug resistance (130). 
Although receptor-independent CPPs have shown promise in cell culture and 
animal studies, the absence of cell specificity hinders their application in clinical studies. 
To apply CPPs for systematic administration, their lack of cell specificity has to be 
bypassed. One method is to control the display of CPPs, that is, shield the CPPs with 
????????????????? during the transport process and expose the CPPs once it arrives at the 
pathological sites. This method uses the tumor environment (MMPs, pH, or PSA) or 
extrinsic (light or heat) to trigger the exposure of CPPs.  
MMPs are overexpressed in some tumors as mentioned above. Tsien and 
coworkers developed a MMP-2 sensitive imaging agent by conjugating CPP oligomer 
arginine with oligomer aspartic/glutamic acid via a -PLGLAG- linker (131). The hairpin 
formed by the electrostatic interaction between the polycationic and polyanionic peptide 
sequences can avoid the nonspecific binding of CPPs to cell membranes. The high 
concentration of MMP-2 in tumors will cleave the -PLGLAG- spacer. The polyanionic 
peptide dissociates from the CPPs, and results in recovery of CPPs?s cell penetrating 
ability (132). Torchilin?s group used a similar idea for drug delivery; they attached long 
poly(ethylene glycol) chain (2 kDa and 3.4 kDa) to the surface of liposomal nanocarriers 
via a octa-peptide (Gly-Pro-Leu-Gly-Ile-Ala-Gly-Gln) spacer to shield the TAT peptide. 
The octa-peptide spacer was cleaved by MMP-2 in the tumor microenvironment, and 
PEG was detached from the nano-carrier surface. Then, the cellular uptake ability of 
CPPs was recovered (133).  
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Using a similar strategy, Torchilin?? group used the pH difference between the 
tumor microenvironment and circulating blood to selectively display cell-penetrating 
TAT peptide in the tumor microenvironment by attaching a long (2 kDa or 3.4 kDa) 
shielding PEG-chains on the surface of liposomes via a pH sensitive hydrazone bond 
(134,135). Bae?s group took advantage of the acidic pH in the tumor microenvironment 
to display the TAT from micelles. One example is to form the PEG-poly(l-lactic acid)-
TAT micelle first, then mix with poly(L-cystine bisamide-g-sulfonamide)-PEG (136). At 
pH 7.4, the ionic interaction between positively charged TAT and negatively charged 
sulfonamide resulted in the assembly of PEG on the surface of micelle to shield TAT. 
When the pH was decreased to 6-6.8, the sulfonamide became neutrally charged. Then, 
TAT was exposed on the micelle surface following the removal of poly(L-cystine 
bisamide-g-sulfonamide)-PEG from the micelle surface. Recently, Shen and colleagues 
used succinic acid to amidize the amine group in TAT (137). This amide bond was stable 
in blood and broken in acidic tumor microenvironment.  
Another interesting stimuli-responsive CPP took advantage of the specific PSA in 
prostate cancer microenvironment (138). Franc group developed activatable protein 
transduction domain conjugates, which incorporated an r8 (positively charged) and r8 
attenuating sequence (negatively charged) by a PSA cleavable linker. This conjugate was 
stable in serum, but disassociated by PSA (138).  
The two most common used extrinsic triggers for display of CPPs are ultraviolet 
(UV) and temperature. One example is to modify the two ends of TAT with two alkyl 
chains via a UV cleavable linker first, then the modified CPPs were anchored to the 
liposomal surface (139). Once they reached the pathological sites, controlled release of 
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the TAT was achieved after the liposome was irradiated with UV. The other example is 
to minimize the nonspecific cellular uptake of CPP by capping the positively charged 
lysine with photo cleavable groups. After being irradiated with UV, the cellular uptake 
ability of the CPP was recovered (140). A new method used thermal triggered micelle 
assembly to adjust the arginine residue density in the micelle corona (141).  
 
1.7.2 Receptor-dependent CPPs (receptor-independent CPP + targeting ligand) 
Targeting moieties are used to enhance the cell specificity of CPPs. The first 
strategy is to decorate the traditional receptor independent CPPs or CPP conjugates with 
additional targeting moieties, which can recognize the receptor on the cancer cell surface. 
The attachment of breast tumor homing cyclic peptide cCPGPEGGAGC to the cell 
penetrating peptide pVEC improved the specific tumor uptake (142). The conjugation of 
anti-HER-2/neu peptide mimetic to the HIV TAT-derived CPP improved the inhibition 
selectivity of the therapeutic peptide STAR3BP toward cancer ErbB2-overexpressing 
breast cancer (143). The attachment of mAb 2C5 to the surface of liposomal nanocarrier 
can selectively deliver TATs to specific tumor cells (133,134). Transferrin receptor 
targeted cell-penetrating peptide (Transportan) is used for targeted delivery of siRNA 
(144).  
 
1.7.3 Receptor-dependent CPPs (iRGD) 
 The second strategy is to integrate the targeting moiety (RGD) and CPP (RGDK) 
together. The best example is iRGD, which was first developed by Ruoslahti?? group. 
The CPP here is the C-end rule peptides (R/KXXR/K), which bind to neuropilin-1 to 
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initiate internalization. This C-end peptide was discovered by mimicking the C-terminal 
of Vascular Endothelial Growth Factor (VEGF)-A165 (145). The carboxyl group in the 
C-terminal arginine plays a critical role for internalization. Blocking this carboxyl group 
by amidation or coupling with another amino acid will abolish the binding and 
penetration ability of the peptide (145). 
 Free iRGD is a cyclic 9-amino acid peptide, which is identified by in vivo phage 
display (146,147). As shown in Figure 1.8, the iRGD penetration is a three-step process 
(146,148). First, the RGD sequence in iRGD binds to ?? integrin. Second, the iRGD 
peptide is converted to cryptic CendR peptide CRGDK/R after being cleaved by cell 
surface associated protease(s). Third, the formed CendR peptide binds to tumor vessel 
signature molecule neuropilin-1 (NRP1) for mediating cell internalization.  
  iRGD has been used for delivery and penetration of small molecule drug, 
polymer conjugates, nanoparticles, and antibodies (149?155). The conjugation of iRGD 
to porous silicon nanoparticles enhanced their cell uptake efficiency in EA.hy926 cells 
(156). The attachment of iRGD on paclitaxel loaded ??????-caprolactone)-b-poly(N-
vinylpyrrolidone) enhanced the penetration and accumulation of paclitaxel in tumor 
tissues (157). iRGD assisted co-delivery of Paclitaxel and survivin shRNA by micelle 
significantly improved the drug accumulation in lung tumor (158). iRGD was also used 
for optical image detection of tumor (159,160). Several conjugation methods have been 
developed to link iRGD to small molecule and macromolecular therapeutics. The most 
commonly used iRGD conjugation reaction is the thiol maleimide reaction between the 

















nanoparticles (146). Also, other derivatives of iRGD are developed to diversity the iRGD 
conjugation (156,161).  
A new peptide CRNGRGPDC was produced by altering the RGDK to RNGR in 
the iRGD framework, and also was able to enhance the penetration of small molecule 
drug and nanomedicine (162).  
 
1.8 Cancer and Chemokines 
1.8.1 Chemokines and chemokine receptors 
 The name of chemokine is an abbreviation of Chemotactic cytokines. Depending 
on the position of first two cysteines at the N-terminus, most small chemokines (8-10 
kDa) are grouped into four families, that is, CXC, CC, C, and CX3 (Figure 1.9) (163). 
Chemokine receptors are seven transmembrane G-protein coupled receptors (GPCR), 
which are able to mediate the migration of cells toward a gradient of chemokines (164). 
Until now, more than 50 chemokines and at least 18 of their receptors have been found 
and investigated (163). A chemokine nomenclature system was proposed by Zlotnik and 





1.8.2 CXCL12 and CXCR4 
The chemokine CXCL12, also known as stromal cell-derived growth factor 1 
















like seven-transmembrane GPCR (164). The specific affinity between CXCL12 and 
CXCR4 is due to the electrostatic interaction between the positively charged CXCL12 
surface and negatively charged CXCR4 extracellular loops (167). As shown in Figure 
1.10, the binding of CXCL12 results in the dimerization of CXCR4, which regulates 
divergent downstream signaling pathways (168). 
 
1.8.3 CXCL12/CXCR4 and cancer 
CXCR4 expression has been reported in at least 23 epithelial, mesenchymal, and 
hematopoietic cancers, including prostate, breast, non-small cell lung (NSCLC), and 
gastric cancers (169?173). The interaction between CXCR4 and CXCL12 plays a pivotal 
role in tumor angiogenesis, growth, and metastasis (174).  
The CXCL12, which is secreted by carcinoma-associated fibroblasts in breast 
tumor, recruits endothelial progenitor cells (EPCs) to promote tumor angiogenesis and 
tumor growth (175). The treatment of CXCR4 antagonist CTCE9908 results in the 
disruption of tumor vasculature, lower expression of VEGF, and decreased recruitment of 
EPCs and neutrophils, thus inhibiting the primary tumor growth (176).  
Metastases lead to more than 90% of solid cancer-related mortality (178). The 
formation of metastasis is a complex series of sequential events: (i) the cancer cells need 
to obtain the invasion ability and escape from the primary tumor; (ii) intravasate into the 
lymph and blood systems, (iii) survive and translocate in the circulation, (iv) extravasate 
(exit from the bloodstream) and adapt to the foreign microenvironment, (v) proliferate at 









Figure 1.10: Signal transduction pathway induced by CXCL12 binding to CXCR4.  








soil hypothesis was first proposed by Paget in 1889 to explain the cancer metastasis 
mechanism (179,180). 
Since Muller and coworkers reported that the CXCL12/CXCR4 axis is involved 
in breast cancer metastasis, much effort has been made to investigate whether the 
CXCL12/CXCR4 is involved in other cancers (170). Quantitative RT-PCR analysis of 
the CXCL12 in major human organs reveals that CXCL12 is highly expressed in bone 
marrow, lymph nodes, liver, and lung, but has a low level of expression in prostate, brain, 
and muscle (170). This coincides with the fact that bone, lymph nodes, liver, and lung are 
the preferential sites for the formation of breast cancer metastases. Now it is believed that 
CXCL12/CXCR4 axis direct the cancer metastasis. The disruption of CXCR4/CXCL12 
is able to inhibit cancer metastasis. The CXCL12 induced invasion ability of MDA-MB-
231 decreased to 16% after silencing the CXCR 4 expression with two siRNAs. The lung 
metastasis in mice reduced to 22% when the injected MDA-MB-231 cells were 
transfected with CXCR4 siRNAs (181).  
 
1.8.4 CXCR4 antagonists in clinical trial 
 Most commonly used agents to block the CXCL12/CXCR4 axis are CXCR4 
antagonists (182). As shown in Table 1.2, several CXCR4 antagonists are being 
evaluated in clinical trials. Because the structures of TG-0054 and POL6326 are not 
publicly disclosed yet, only five CXCR4 antagonists are discussed below: MSX-122, 
CTCE9908, AMD3100, AMD070 (AMD11070), BKT140.  
 As shown in Figure 1.11.A, AMD3100 (Plerixafor/MozobilTM) consists of two 


















Agents Phase Indication Sponsor
TG-­0054 Phase  II
Hematopoietic  stem  cell  mobilization  in  patients  
with  multiple  myeloma,  non-­Hodgkin  lymphoma  
or  Hodgkin  disease
TaiGen  Biotechnology  Co.,  Ltd
POL6326 Phase  II Cell  mobilization  and  healing  in  acute  myocardial  infarction Polyphor  Ltd
POL6326 Phase  I Mobilization  of  hematopoietic  stem  cells  in  healthy  volunteers Polyphor  Ltd
CTCE-­9908 Phase  I/II Advanced  solid  tumors Chemokine  Therapeutics  Co.
MSX-­122 Phase  I Refractory  metastatic  or  locally  advanced  solid  tumor Metastatix,  Inc
Plerixafor FDA  approved
Hematopoetic  stem  cell  mobilization  in  patients  
with  non-­Hodgkin?s  lymphoma  and  multiple  
myelome
Genozyme
Plerixafor Phase  I Gioma,  Acute  Myeloid  Leukemia,  Chronic  Lymphocytic  Leukemia Genozyme
Plerixafor Phase  I Myelokathexis  (WHIM  syndrome) Genozyme
AMD070 Phase  I/II HIV  infections National  Institute  of  Allergy  and  Infectious  Disease
BKT140 Phase  I/II Multiple  myeloma Biokine  Therapeutics  Ltd
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which has been approved by the FDA to mobilize hematopoietic stem cells to the 
peripheral blood in combination with granulocyte colony-stimulating factor (G-CSF) 
(183). The specificity of AMD3100 toward CXCR4 is due to the electrostatic interaction 
between the positively charged nitrogen in the AMD3100 cyclam ring and the negatively 
charged Asp171, Asp262, and Glu288 residues in the CXCR4 receptor (184,185). The 
incorporation of metal ions Cu2+, Zn2+, or Ni2+ into AMD3100 significantly enhanced 
?????????? ???????? ????????? ??????? ?????? ????????? ???? ???????? ????????????? ????
electrostatic interaction between AMD3100 and CXCR4 (186). AMD3100 inhibits the 
migration and invasiveness of prostate cancer cells, which was promoted by CXCL12 
(44). One of the obvious limitations of AMD3100 is its short half life (3.5 to 4.9 h) (187).  
 AMD070 is also known as AMD11070. The structure of AMD070 is shown in 
Figure 1.11. B. It is the first orally bioavailable CXCR4 antagonist.  Molecular modeling 
explained the possible interaction mechanism between AMD 070 and CXCR4 (189). The 
binding affinity of AMD070 and CXCR4 is from the electronic interaction between the 
protonated primary amine in AMD070 and one of Asp residues (Asp97, Asp171, Asp262), 
and the pi stack interaction in AMD070 and Tyr45 and Trp94 residues (189). AMD 070 
has shown promising in preventing melanoma metastasis to liver by blocking the 
CXCR4-CXCL12 axis (190). AMD070 is better than AMD3100 in blocking the CXCL12 
inducing migration of human acute lymphoblastic leukemia cells (191).   
MSX-122 is a novel orally bio-available small molecular weight CXCR4 
antagonist. The chemical name of MSX is N, N-9-(1,4-phenylenebis(methylene)) 
dipyrimidine-2-?????????????????????????????????????????????????????????????? ?????????????










Figure 1.11: Structure of CXCR4 antagonists in clinical trials. (A) AMD3100;  











































 significantly reduce the formation of radiation-induced pulmonary fibrosis by disrupting 
the CXCL12/CXCR4 interaction (193). However, there is no reported mechanism to 
explain this interaction. A Phase I clinical study of MSX-122 was started in 2007, but 
was suspended in 2008 due to the unmanageable toxicities (188,194).  
 As shown in Figure 1.11.D, CTCE9908 is a dimer peptide comprised of two of 
the first 8 amino acids of the N-terminal sequence of CXCL12. Subcutaneous 
administration of CTCE-9908 into mice bearing MDA-MB-231 xenograft tumors 
reduced the growth of both primary and metastatic breast tumors (195). Systemic 
delivery of CTCE9908 via oncolytic vaccinia virus for treatment of BALB/c mice with 
4T1 breast tumor xenograft not only inhibited the growth of orthotopic primary tumors 
but also reduced lung metastasis (176). CTCE-9908 also blocked the CXCL-12 induced 
ovarian cancer cell migration and killed the CXCR4 positive ovarian cancer cells by 
mitotic catastrophe (196). CTCE-9908 inhibited the proliferation of prostate cancer cells 
in vitro and the growth of prostate tumor in vivo (197).  
 BKT140 belongs to T140 series peptide (Figure 1.12). T140 peptides are another 
type of potent CXCR4 antagonists, which were originally developed to inhibit the T-cell 
line-tropic HIV infection (198). T140 series are considered to be the most active CXCR4 
antagonists (199). Fujii and coworkers used the traditional Ala-subsitution scanning to 
investigate the structure-activity relationship between T140 peptides and CXCR4 (198). 
They found that four indispensable amino acid residues (Arg2, Nal3, Tyr5, and Arg14) are 








Figure 1.12: Structures of T140 series peptides. T140 (A), TN14003 (B), and BKT140 






 However, two major drawbacks are associated with T140 peptide. First, the loss 
of carboxyl terminal Arg14 from T140 in serum results in loss of T140 activity. Second, 
the electrostatic interaction between the positively charged peptide (Arg1, Arg2, Arg6, 
Lys7, D-Lys8, Arg11, and Arg14) and negatively charged cell membrane may lead to non-
specific binding (200). To improve the serum stability and reduce the nonspecific cell 
cytotoxicity, another effective CXCR4 inhibitor (TN14003) was developed by C- 
terminal amidation and replacement of the basic Arg6 with non-basic Cit6 (201).  After  
further modification, a new CXCR4 antagonist 4F-benzoyl-TN14003 (BKT140)  with 
low IC50 (0.99 nM) was discovered (202).  
 
1.9 HPMA Copolymer-drug Conjugates 
 Polymeric therapeutics belong to the first-generation nanomedicines (203). The 
first synthetic polymer-drug conjugates in Phase I/II clinical trial were N-(2-
hydroxylpropyl)methacrylamide (HPMA) copolymer-doxorubicin conjugates (203). 
HPMA polymer was first prepared by Kope?ek and coworkers in 1973, and the first 
HPMA copolymer drug conjugate was published in 1979 (204,205). In the past three 
decades, water soluble and biocompatible HPMA polymers have been utilized to deliver 
several anticancer drugs including doxorubicin, paclitaxel, docetaxel, camptothecin, 
geldanamycin, daunomycin, gemcitabine, etc. (206). The drug was conjugated to HPMA 
copolymer via a pH sensitive bond (hydrazone) or lysosomal cleavable tetrapeptide 
spacer (-GFLG-) (207?209). This section will briefly discuss the architecture, synthesis, 





1.9.1 Architectures of HPMA copolymer-drug conjugates 
 ?????? ???????? ???????????? ????????????s determine their physicochemical 
properties, HPMA copolymer-drug conjugates also have been developed using various 
architectures including linear, branched, cross-linked, brush, etc. (210). Most of the linear 
HPMA copolymer-drug conjugates were random copolymers with random conformation 
(211?213). Some of the linear HPMA copolymers were di-block copolymers (214?216). 
HPMA-based di-block copolymer self-assembled to form a micelle if one block was 
hydrophilic and the other block was hydrophobic (214,217). Core-cross linking strategies 
were used to increase the stability of HPMA-based micelles during circulation (218,219). 
One of the typical examples of branched HPMA copolymer-drug conjugates is the star-
shaped HPMA copolymer-doxorubicin (DOX) conjugate, which was formed by grafting 
poly(amidoamine) (PAMAM) dendrimers with semitelechelic HPMA copolymers 
bearing DOX (220). HPMA-oligolysine brush polymers have been used for nucleic acid 
delivery, and the formed polyplex morphology of brush polymers and plasmid DNA 
impacted nucleic acid transfection efficiency (221).  
 
1.9.2 Preparation of HPMA copolymer-drug conjugates 
 HPMA copolymer-drug conjugates can be prepared via co-polymerization or 
polymer-analogous attachment (222,223). No matter which strategy is used for preparing 
HPMA copolymer-drug conjugates, radical polymerization is one of the most powerful 
tools to prepare HPMA copolymer-drug conjugates or their precursors. The radical 
polymerization consists of conventional radical polymerization and reversible-
deactivation radical polymerizations (RDRP). The major RDRP includes reversible 
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addition-fragmentation chain transfer polymerization (RAFT), atom transfer radical 
polymerization (ATRP), nitroxide radical polymerization (NMP), and ring-opening 
polymerization (ROMP) (224). Most of the HPMA copolymer-drug conjugates were 
prepared by conventional radical and RAFT polymerization (223). Before the emergence 
of RDRP, conventional radical polymerization was the major tool for preparing HPMA 
copolymer-drug conjugates. However, conventional radical polymerization cannot 
control the molecular weight distribution, copolymer composition, and macromolecular 
architecture (225). 
 The RAFT polymerization was first reported by the scientists at Commonwealth 
Scientific and Industrial Research Organization (CSIRO) (Australia) in early 1998 (226). 
The McCormick group first utilized RAFT polymerization to prepare well-controlled 
HPMA polymers (Mn = 97 kDa, Mw/Mn = 1.07) (227). In addition to controlling the 
molecular weight and molecular weight distribution, the other advantage of RAFT 
polymerization is that RAFT polymerization can freely be used to prepare diblock, 
triblock, even multiblock HPMA copolymer drug conjugates (216,217,228). The 
limitation of RAFT polymerization is that its success depends upon the selection of the 
chain transfer agent for the monomers and reaction conditions [211]. The generally 
accepted RAFT polymerization mechanism is shown in Figure 1.13. 
 The RAFT polymerization consists of a sequence of steps: initiation, initial 
equilibrium, re-initiation, main equilibrium, and termination (229). The general initiation 
procedure starts from the decomposition of azo initiator into two radical fragments, and 
then reacts with monomer to produce propagating polymeric radical (Pm ?) (230). In the 











form an intermediate adduct radical 2 (230). Then the intermediate radical 2 fragments to 
yield either the starting species or a radical (??) and a polymeric RAFT agent (S=C(Z)S-
Pm) (230). In the reinitiation procedure, the liberated ??????????????????s with monomer to 
form a new propagating radical (Pn ?) (231). In the main RAFT equilibrium, propagating 
radical (Pn ?) reacts with polymeric RAFT agent (S=C(Z)S-Pm) to form an intermediate 
radical 4 (232). The formation and decomposition of intermediate radical 4 is a reversible 
process. Importantly, the intermediate radical 4 fragment equally in either direction (232). 
Then all polymer chains have equal opportunities for growth, and thus narrow 
polydispersities (232). The termination of RAFT polymerization includes two 
mechanisms: coupling and disproportionation. 
 
1.9.3 Characterization of HPMA copolymer-drug conjugates 
 The physicochemical properties of HPMA copolymer-drug conjugates determine 
???? ???????????? ???????????????? (233). The physicochemical properties of HPMA 
copolymer-drug conjugates include: molecular weight and molecular weight distribution, 
hydrodynamic radius, surface charge, functional groups, drug contents, morphology, etc. 
Size exclusion chromatography with a commercial column is usually used for measuring 
the molecular weight and molecular weight distribution of HPMA copolymer-drug 
conjugates (234). The hydrodynamic radius (RH) of HPMA copolymer-drug conjugate is 
determined by dynamic light scattering (DLS) (235,236). For example, two HPMA 
copolymers with weight-average molecular weight (26 ± 2.0 kDa and 52 ± 5.0 kDa) had 
average hydrodynamic radii 1.4 ± 0.0 nm and 3.3 ± 0.2 nm, respectively [234]. The 
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morphology of HPMA copolymer drug conjugate core-shell nanoparticles or micelles 
was further measured with transmission electron microscope (TEM) (221,236).  
 The mechanism by which DLS can be used to measure polymer conjugates? 
hydrodynamic radius (RH) will be briefly introduced. This application is based on the 
assumption that the conjugate molecules in solution are undergoing Brownian motion 
(237). The larger the conjugates, the slower the Brownian motion (diffusion velocity) will 
be. The hydrodynamic radius (RH) of conjugate is calculated from its diffusion coefficient 
(D) using the well-known Stokes-Einstein relationship: 
RH=(kBT?????D 
where kB is the Boltzmann constant, T is the absolute temperature, and ? is the viscosity 
of solution (238).  
 Overall, this section briefly introduced the architecture, preparation, and physico-
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TARGETED HPMA COPOLYMER-DOCETAXEL CONJUGATES FOR  
PROSTATE-SPECIFIC MEMBRANE ANTIGEN EXPRESSING  
PROSTATE CANCER TREATMENT 1 
 
2.1 Summary 
 Combination of targeted delivery and controlled release is a powerful technique 
for cancer treatment. Here, we describe the design, synthesis, structure validation, and 
biological properties of targeted and nontargeted N-(2-hydroxypropyl)methacrylamide 
(HPMA) copolymer docetaxel conjugates. Docetaxel (DTX) was conjugated to HPMA 
copolymer via a tetrapeptide spacer (-GFLG-). 3-(1,3-dicarboxypropyl)-
ureido]pentanedioic acid (DUPA) was used as the targeting moiety to actively deliver 
DTX for treatment of  Prostate-Specific Membrane Antigen (PSMA) expressing prostate 
cancer. Short and long spacer DUPA monomers were prepared, and four HPMA 
copolymer-DTX conjugates (nontargeted, two targeted with short spacer, and targeted 
with long spacer) were prepared via Reversible Addition-Fragmentation Chain Transfer 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  This chapter has been modified with permission from the following publication: Peng 
ZH, Sima M, Salama ME, ???????????, ?????????. Spacer length impacts the efficacy 
of targeted docetaxel conjugates in prostate-specific membrane antigen expressing 
prostate cancer. J Drug Target. 2013, 21(10): 968-80.  	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(RAFT) copolymerization. Following confirmation of PSMA expression on C4-2 cell 
?????? ???????????????????? in vitro cytotoxicity was tested against C4-2 tumor cells and 
their anticancer efficacies were assessed in nude mice bearing s.c. human prostate 
adenocarcinoma C4-2 xenografts. The in vivo results show that the spacer length between 
targeting moieties and HPMA copolymer backbone can significantly affect the treatment 
efficacy of DTX conjugates against C4-2 tumor bearing nu/nu mice. Moreover, 
histological analysis indicated that the DUPA targeted DTX conjugate with longer spacer 
had no toxicity in major organs of treated mice. 
 
2.2 Introduction 
Prostate cancer is the most common malignant cancer and the second leading 
cause of cancer-related death among men in the United States. It was estimated that 
238,590 Americans will be newly diagnosed with prostate cancer and 29,720 Americans 
will die from prostate cancer in 2013 (1). Although several therapeutic strategies, 
including radical prostatectomy, androgen deprivation, chemotherapy, bone-directed 
therapy, and radiation therapy have been available for prostate cancer treatment, they are 
ineffective against advanced prostate cancer and also associated with severe side effects 
(2). DTX, the first line chemotherapy for prostate cancer treatment, is associated with 
fatigue, nausea or vomiting or both, alopecia, diarrhea, nail changes, sensory neuropathy, 
anorexia, changes in taste, stomatitis, dyspnea, tearing, peripheral edema, and epistaxis 
(3). One of the major reasons for these side effects is that DTX distributes 
indiscriminately into all cells of the body and causes damage to malignant and healthy 
cells alike. Although DTX benefit for patients with metastatic castration-resistant prostate 
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cancer (CRPC), the overall survival improvement is mild (~ 2.5 months) (4). The 
significant mortality and morbidity of prostate cancer urgently require development of 
novel, safer, and more potent formulations of DTX therapeutics. The recently developed 
nano-medicine technology can help to mitigate the off-target and dose limiting effects of 
small molecule therapeutics and enhance antitumor efficacy through polymer conjugate 
delivery system, especially decoration of the conjugate with a targeting ligand can 
provide the most effective therapy (5,6).  
The most appealing antigen for treatment and diagnosis of prostate cancer is 
prostate-specific membrane antigen (PSMA) because: (i) PSMA presented at the cell 
surface but not shed into the circulation; (ii) PSMA enzyme activity in prostate cancer 
sample was about 10-fold higher than that in benign prostatic hyperplasia (BPH) and 
normal tissue (7); (iii) its expression on prostate cancer was about 1000-fold higher than 
the minimal expression in other tissues such as kidney, proximal small intestine, salivary 
gland (8); (iii) its expression increased with disease progression (9).  
Therefore, several classes of ligands including aptamers (10?12), antibodies (13?
16), peptides (17,18), and small molecules (19,20) have been developed to deliver 
therapeutics (21) and imaging agents (22?24) for diagnosis and treatment of PSMA 
expressing prostate cancer. Phosphoramidate and glutamate ureas are two major classes 
of small-molecule ligands that can bind PSMA selectively and with high affinity (25,26). 
However, the majority of their applications focus on imaging prostate cancer on murine 
models (22?24). Few efforts have used small-molecule anti-PSMA ligands for treatment 
studies in mice models, maybe due to the challenging chemistry for small molecule 
ligands modification (21,27,28). 
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 In the present study, we choose 3-(1,3-dicarboxypropyl)-ureido]pentanedioic acid 
(DUPA) as the targeting moiety because of its favorable characteristics: multivalency, 
low cost, reproducible chemical synthesis, nonimmunogenicity, high permeability in 
solid tumors, and fast clearance from normal tissue. DUPA belongs to a class of 
glutamate ureas (19,20); it is comparatively easy to modify the R group at C-2 position. 
We therefore reasoned that we might be able to incorporate a spacer at this position to 
connect the polymer-drug conjugate and DUPA targeting moiety. Because the active site 
of PSMA is about 20 Å depth in the PSMA, we hypothesized a reasonable length of 
spacer is required between DUPA targeting moiety and drug carrier (29,30). 
Based on the above considerations, we were interested in using DUPA as the 
targeting moiety to actively deliver DTX for treatment of PSMA expressing prostate 
cancer. DUPA and DTX were incorporated into the uncharged, hydrophilic, and 
biocompatible HPMA copolymer via a suitable spacer length linker and lysosomally 
degradable spacer (-GFLG-), respectively (31,32). We hypothesized that conjugation of 
the targeting moiety DUPA to HPMA copolymer will enhance the ligands opportunity to 
bind to PSMA by increasing the circulation time of DUPA. The overall goal of the 
combination of targeted delivery and controlled release of DTX is to enhance its 
antitumor efficacy and lower its toxicity. Herein, we designed, synthesized, and 
characterized polymerizable derivatives of DTX and DUPA (short and long spacer). We 
synthesized the DUPA targeted or nontargeted HPMA copolymer - DTX conjugates and 
assessed their anticancer efficacies in nude mice bearing s.c. human prostate 
adenocarcinoma C4-2 xenografts. We also tested the toxicity of DTX conjugates by 
monitoring mice body weight changes and using a histological assay.  
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2.3 Materials and Methods 
2.3.1 Materials 
 DTX was purchased from AK Scientific (Union City, CA). N-(3-aminopropyl) 
methacrylamide (APMA) was purchased from PolySciences (Warrington, PA).  Initiator 
????-azobis(2,4-dimethylvaleronitrile) (V-65) and azobisisobutyronitrile (AIBN) were 
purchased from Wako Pure Chemicals (Richmond, VA).  L-glutamate di-tert-butyl ester 
hydrochloride, O-(7-azabenzotriazol-1-yl)-N,N,N??N?-tetramethyluronium hexafluoro - 
phosphate (HATU), 4-dimethylaminopyridine (DMAP), and 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC) were purchased from 
AAPPTec (Louisville, KY). L-glutamic acid benzyl ester ?-tert-butyl ester was purchased 
from Chem-Impex International (Wood Dale, IL). 1-(9H-fluoren-9-yl)-3-oxo-
2,7,10,13,16,19,22,25,28,31,34,37,40-tridecaoxa-4-azatritetracontan-43-oic acid (Fmoc-
NH-EG12-COOH) was purchased from Peptides International (Louisville, KY). Monomer 
HPMA (33), N-methacryloyl-Gly-Phe-Leu-Gly-OH (MA-GFLG-OH) (34), and chain 
transfer agent 4-cyanopentanoic acid dithiobenzoate (CPAD) (35) were prepared as 
described in the literature. All other reagents were purchased from Sigma Aldrich (St. 
Louis, MO) if not otherwise mentioned. 
 
2.3.2 Synthesis of N-methacryloylglycylphenylalanylleucylglycyl-Docetaxel 
 The scheme for synthesis of N-methacryloylglycylphenylalanylleucylglycyl 
Docetaxel (MA-GFLG-DTX) is shown in Figure 2.1. A solution of MA-GFLG-OH 
(920.5 mg, 2 mmol), DTX (807.4 mg, 1 mmol), and DMAP (146.6 mg, 1.2 mmol) in 





















mmol) was added at 0°C. The reaction mixture was stirred at 0°C for 2 h, then allowed to 
warm to room temperature and stirred at room temperature for additional 22 h. The 
reaction mixture was washed with water three times, brine once, and dried over 
anhydrous sodium sulfate. After removing the solvent under reduced pressure, the crude 
residue was purified by column chromatography (silica gel 60 Å, 200-400 mesh; ethyl 
acetate: hexane = 1:4, 1:1, 100% ethyl acetate) to obtain 800 mg pure product with 64% 
yield. The structure of the product was validated by matrix assisted laser 
desorption/ionization-time of flight (MALDI-TOF) mass spectroscopy (MS) (Figure 2.2). 
MALDI-TOF MS: calcd for C66H83N5NaO19 ([M + Na]+) 1273.4, found 1273.8; calcd for 
C66H83N5KO19 ([M + K]+), 1289.5, found 1289.8. 
 
2.3.3 Synthesis of (3S,7S)-17-methyl-5,10,16-trioxo-4,6,11,15-tetraazaoctadec-17-ene-
1,3,7-tricarboxylic acid 
 The synthesis procedure of (3S,7S)-17-methyl-5,10,16-trioxo-4,6,11,15-
tetraazaoctadec-17-ene-1,3,7-tricarboxylic acid (MA-DUPA) is schematically shown in 
Figure 2.3. Numbers of compounds used in the description below also relate to Figure 2.3. 
 
2.3.3.1 Synthesis of ((S)-5-benzyl 1-tert-butyl 2-(3-((S)-1,5-di-tert-butoxy-1,5-
dioxopentan-2-yl)ureido) pentanedioate) (Compound 4)  
 To a dried three-neck flask was added L-glutamate di-ter t-butyl ester 
hydrochloride (1; 2.5 g, 8.45 mmol) and 100 mL of DCM under nitrogen atmosphere. 
After the solution was cooled to -65 oC, triphosgene (2; 830 mg, 2.8 mmol) and 2.5 mL 

























gradually raised from -65 oC to 10 oC under the protection of nitrogen. The solution was 
recooled to -65 oC before adding a solution of L-Glu(OBn)-OtBu (3; 3 g, 9.1 mmol) and 
triethylamine (1.5 mL) in DCM (50 mL). The reaction mixture was allowed to increase to 
room temperature over a period of 2 h and stirred at room temperature overnight. The 
reaction was quenched with 1 M HCl, and the organic layer was washed with water, brine, 
and dried over anhydrous sodium sulfate. The crude product was purified using flash 
chromatography to obtain 2.95 g (60.3%) of product as colorless oil.  
 
2.3.3.2 Synthesis of (S)-5-tert-butoxy-4-(3-((S)-1,5-di-tert-butoxy-1,5-dioxopentan-2-
yl)ureido)-5-oxopentanoic acid (Compound 5) 
  ((S)-5-benzyl 1-tert-butyl 2-(3-((S)-1,5-di-tert-butoxy-1, 5-dioxopentan-2-
yl)ureido) pentanedioate) (4; 1 g, 1.73 mmol) was dissolved in 30 mL of DCM, then 10% 
Pd/C (200 mg) was added into this solution. The reaction mixture was hydrogenated at 1 
atm for 28 h at room temperature. Pd/C was filtered through a Celite pad and washed 
with DCM. The crude product was purified by using flash chromatography (silica gel; 
hexane: ethyl acetate = 4:1, 2:1, 1:1) to obtain the desired product as white solid (590 mg, 
70% yield). The product was checked with 1H NMR (Figure 2.4A) and MS (Figure 2.4B). 
1H NMR (CDCl3): ? 6.0 (d, J = 8.4 Hz, 1H); 5.52 (d, J = 8.4 Hz, 1H); 4.51-4.42 (m, 1H); 
4.34-4.28 (m, 1H); 2.47-2.35 (m, 2H); 2.34-2.26 (m, 2H); 2.18-2.04 (m, 2H); 1.94-1.78 
(m, 2H); 1.48 (s, 9H), 1.45 (s, 9H); 1.42 (s, 9H). High resolution mass spectrometry 











Figure 2.4: Mass (A) and 1H NMR (B) spectra of (S)-5-tert-butoxy-4- 
(3-((S)-1,5-di-tert-butoxy-1,5-dioxopentan-2-yl)ureido) 








2.3.3.3 Synthesis of (3S, 7S)-tri-tert-butyl 17-methyl-5,10,16-trioxo-4,6,11,15-
tetraazaoctadec-17-ene-1,3,7-tricarboxylate (Compound 7) 
 (S)-5-tert-butoxy-4-(3-((S)-1,5-di-tert-butoxy-1,5-dioxopentan-2-yl)ureido)-5-
oxopentanoic acid (5; 817 mg, 1.67 mmol), APMA (6; 329 mg, 1.84 mmol), HATU (700 
mg, 1.84 mmol), N, N-diisopropylethylamine (DIPEA) (321 µL, 1.84 mmol), and DCM 
were added into 50 mL flask, then this mixture was stirred at room temperature overnight.  
Water was added into this mixture, then the organic phase was washed with water and 
brine. Then the organic phase was dried over anhydrous sodium sulfate, filtered, and 
concentrated under vacuum. The crude product was loaded on silica gel and was purified 
using flash chromatography (silica gel; hexane: ethyl acetate=1:1; 100% of ethyl acetate; 
30% methanol in DCM) to obtain 841 mg (yield = 82.2%) of product. The product was 
characterized with 1H NMR (Figure 2.5A) and MS (Figure 2.5B). 1H NMR (400 MHz, 
D2???????????????J = 6 Hz, J = 6.4 Hz, 1H), 7.02 (t, J = 6 Hz, J = 6.4 Hz, 1H), 5.79 (s, 1H), 
5.57 (d, J = 8 Hz, 1H), 5.47 (d, J = 8 Hz, 1H), 5.33 (s, 1H), 4.32-4.25 (m, 2H), 3.38-3.26 
(m, 4H), 2.39-2.22 (m, 4H), 2.20-2.02 (m, 2H), 1.98 (s, 3H), 1.85-1.75 (m, 2H), 1.72-
1.64 (m, 2H), 1.47 (s, 9H), 1.44 (s, 9H); 1.42 (s, 9H). HRMS (ESI+): calcd for 
C30H52N4O9Na [M+Na]+, 635.3632; found, 635.3641. 
 
2.3.3.4 Deprotection of compound 7 to produce MA-DUPA 
 To a microwave reaction tube was added (3S, 7S)-tri-tert-butyl 17-methyl-
5,10,16-trioxo-4,6,11,15-tetraazaoctadec-17-ene-1,3,7-tricarboxylate (7; 150 mg, 0.245 
mmol), 1 mL of DCM, 2 mL of trifluoroacetic acid (TFA), and stirrer bar. The tube was 










Figure 2.5: 1H NMR (A) and mass (B) spectra of (3S, 7S)-tri-tert-butyl 17-methyl-
5,10,16-trioxo-4,6,11,15-tetraazaoctadec-17-ene-1,3,7- 









for 2.5 min. After being cooled to room temperature and concentrated under reduced 
pressure, the crude product was precipitated in diethyl ether. After being dried under air 
and purified with HPLC, 79.3 mg (72.9%) of pure product was obtained. The product 
was characterized with 1H NMR (Figure 2.6A) and MS (Figure 2.6B).  1H NMR (400 
MHz, D2????????????????????????????????????????????J = 9.2 Hz, 5.2 Hz, 1H), 4.03 (dd, J = 
9.2 Hz, 4.4 Hz, 1H), 3.10 (t, J = 7.2 Hz, 2H), 3.05 (t, J = 6 Hz, 2H), 2.35 (t, J = 6 Hz, 2H), 
2.20 (t, J = 6.8 Hz, 2H), 2.08-1.96 (m, 2H), 1.86-1.76 (m, 2H), 1.75 (s, 3H), 1.60-1.52 (m, 
2H). MS (ESI+): calcd for C18H28N4NaO9 ([M + Na]+) 467.2, found 467.3. 
 
2.3.4 Synthesis of (3S,7S)-57-methyl-5,10,50,56-tetraoxo 14,17,20,23,26,29,32, 35,38,41, 
44,47-dodecaoxa-4,6,11,51,55-pentaazaoctapentacont-57-ene-1,3,7-tricarboxylic  acid 
(MA-EG12-DUPA) 
 The synthesis procedure of (3S,7S)-57-methyl-5,10,50,56-tetraoxo-
14,17,20,23,26,29, 32,35,38,41,44,47-dodecaoxa-4,6,11,51,55-pentaazaoctapentacont-57-
ene-1,3,7-tricarboxylic acid (MA-EG12-DUPA) is schematically shown in Figure 2.7. 
Numbers of compounds used in the description below also relate to Figure 2.7. 
 
2.3.4.1 Synthesis of 1-amino-N-(3-methacrylamidopropyl)-3,6,9,12,15,18,21,24,27,30, 
33,36-dodecaoxanonatriacontan-39-amide (MA-EG12-NH2) 
 To a carefully dried three-neck flask was added Fmoc-NH-EG12-COOH (8; 90 
mg, 0.11 mmol), HATU (82 mg, 0.22 mmol), and 2 mL DCM, and then the mixture was 
stirred for about 2 h.  Then APMA (6; 38 mg, 0.22 mmol) and DIPEA (56 µL, 0.33 mmol) 

























Figure 2.7: Synthetic scheme and structure of monomer MA-EG12-DUPA. 
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brine once, and dried over anhydrous sodium sulfate. The product MA-EG12-NHFmoc (9, 
43 mg) was obtained with a yield 41%.  
 The obtained 43 mg of MA-EG12-NHFmoc was redissolved in a mixture of 
DMF (1 mL) and piperidine (0.25 mL), then this mixture was stirred at room temperature 
for about 8 h. After removing the solvent, the remaining crude product was purified with 
flash chromatography on silica gel using methanol/DCM as eluent to provide the product 
MA-EG12-NH2 (10; 10 mg, 33%).  
 
2.3.4.2 Synthesis of (3S,7S) tri-tert-butyl 57-methyl-5,10,50,56-tetraoxo-14,17,20,23,26, 
29,32,35,38,41,44,47-dodecaoxa-4,6,11,51,55-pentaazaoctapentacont-57-ene-1,3,7-
tricarboxylate (MA-EG12-DUPA(tri-tert-butyl); 11) 
 To a carefully dried three-neck flask was added (S)-5-tert-butoxy-4-(3-((S)-1,5-
di-tert-butoxy-1,5-dioxopentan-2-yl)ureido)-5-oxopentanoic acid (5; 658.5 mg, 1.35 
mmol), HATU (512.4 mg, 1.35 mmol), and 2 mL DCM, then the mixture was stirred for 
about 30 min. Then MA-EG12-NH2 (10; 500 mg, 0.67 mmol) and DIPEA (352 µL, 2.02 
mmol) were added and stirred overnight. After removing the solvent, the crude product 
was purified with silica gel column with gradient solvent to afford 600 mg of desired 
products with the yield of 81.3%. The product was characterized with mass spectroscopy 
(Figure 2.8). TOF-MS (ESI+): calcd for C57H106N5O22 ([M + H]+), 1212.7, found 1212.8; 
calcd for C57H109N6O22 ([M + NH4]+), 1229.8, found 1229.8; calcd for C57H105N5NaO22 





















2.3.4.3 Deprotection of compound 11 to produce MA-EG12-DUPA 
 MA-EG12-DUPA(tri-tert-butyl) (11; 100 mg, 0.082 mmol) in a mixture of 
solvent (DCM/TFA=1/2) (3mL) was kept in a microwave reaction sealed tube. After 
being prestirred for 30 sec, the reaction was conducted at 50 oC for 2 min in a microwave 
reactor. After removing the solvent under reduced pressure, the remaining crude product 
was precipitated in diethyl ether. After being purified with semipreparative HPLC, pure 
product (42 mg) was obtained in 48.8% yield. The product was characterized with mass 
spectroscopy (Figure 2.9). ESI-: calcd for C45H80N5O22 ([M-H]-), 1042.5. Found: 1042.5.  
 
2.3.5 Preparation of DUPA-targeted and nontargeted HPMA  
copolymer-DTX conjugates  
 DUPA-targeted and nontargeted HPMA copolymer-DTX conjugates were 
prepared with RAFT polymerization.  
 
2.3.5.1 Preparation of nontargeted HPMA copolymer-DTX conjugate P-DTX 
 The scheme for preparation of nontargeted HPMA copolymer-DTX conjugate P-
DTX is shown in Figure 2.10. To an ampoule was added monomer HPMA (357 mg, 
2.496 mmol), MA-GFLG-DTX (80 mg, 0.064 mmol), CPAD (0.716 mg), 
azobisisobutyronitrile (AIBN) (0.084 mg), and methanol (1.5 mL). Then this mixture was 
bubbled with nitrogen for 30 min and the ampoule was sealed. The RAFT 
copolymerization was conducted at 55 °C for 79 h. The resulting copolymer was 
precipitated in diethyl ether and purified by preparative FPLC. After freeze-drying, 84.7 




















Figure 2.10: Synthetic scheme (A) and size exclusion chromatography 
 (SEC) profile (B) of P-DTX.  
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2.3.5.2 Preparation of DUPA-targeted HPMA copolymer-DTX  
conjugate P-DTX-DUPA (Low MW) 
 The synthetic scheme for preparing low molecular weight DUPA-targeted HPMA 
copolymer-DTX conjugate P-DTX-DUPA is shown in Figure 2.11. To an ampoule was 
added monomer HPMA (238.7 mg, 1.667 mmol), MA-GFLG-DTX (56.7 mg, 0.045 
mmol), MA-DUPA (47 mg, 0.106 mmol), and a solution of 0.9 mg CPAD or 0.167 mg of 
V-65 in DMSO. Then more of DMSO and DI water were added until the final volume of 
DMSO and DI water were 1.8 mL and 1.2 mL, respectively. The mixture was bubbled 
with nitrogen for 30 min before sealing the ampoule. The RAFT copolymerization was 
conducted at 52 °C for 36 h. The resulting copolymer was precipitated in diethyl ether 
and purified by preparative FPLC. After freeze-drying, 110 mg of product was obtained 
(32% in yield). 
 
2.3.5.3 Preparation of DUPA-targeted HPMA copolymer-DTX  
conjugate P-DTX-mDUPA (High MW) 
 The scheme for preparing DUPA-targeted HPMA copolymer-DTX conjugate P-
DTX-mDUPA with high molecular weight is shown in Figure 2.12. To an ampoule was 
added monomer HPMA (338.8 mg, 2.366 mmol), MA-GFLG-DTX (80 mg, 0.064 mmol), 
MA-DUPA (57.58 mg, 0.130 mmol), CPAD (0.716 mg), azobisisobutyronitrile (AIBN) 
(0.084 mg), and methanol (1.5 mL). Then this mixture was bubbled with nitrogen for 30 
min and the ampoule was sealed. The RAFT copolymerization was conducted at 55 °C 
for 79 h. The resulting copolymer was precipitated in diethyl ether and purified by 











































2.3.5.4 Preparation of DUPA-targeted HPMA copolymer-DTX  
conjugate P-DTX-EG12-DUPA 
 The synthetic scheme for preparing DUPA-targeted HPMA copolymer-DTX 
conjugate P-DTX-EG12-DUPA is shown in Figure 2.13. The general procedure is: (i) 
added monomer HPMA (238.7 mg, 1.667 mmol), MA-EG12-DUPA (100 mg, 0.096 
mmol), and MA-GFLG-DTX (56.7 mg, 0.045 mmol) into an ampoule; (ii) added a 
solution of 0.9 mg CPAD in DMSO and 0.167 mg of V-65 in DMSO; (iii) added more of 
DMSO and DI water until the final volume of DMSO was 1.8 mL and final volume of DI 
water was 1.2 mL; (iv) bubbled the mixture with nitrogen for 30 min before sealing the 
ampoule; (iv) the RAFT copolymerization was conducted at 52 °C for 36 h. The resulting 
copolymer was precipitated in diethyl ether and purified by preparative FPLC. After 
freeze-drying, 138 mg of product was obtained (35% in yield). 
 
2.3.6 Characterization of DUPA-targeted and nontargeted  
HPMA copolymer-DTX conjugates 
 The number average molecular weight (Mn), weight average molecular weight 
(Mw) and polydispersity (Mw/Mn) of DUPA-targeted or non-targeted HPMA copolymer-
DTX conjugates were analyzed by size exclusion chromatography using a Superose 6 
HR10/30 analytical column on an AKTA FPLC system (Pharmacia) equipped with 
refractive index (Optilab rEX) and light scattering MiniDawn TREOS detectors (Wyatt 
Technology Inc, Santa Barbara). The buffer with 0.1 M of sodium acetate in a mixture of 













was 0.4 mL/min. HPMA homopolymer fractions were used as molecular weight 
standards. 
The DTX content in DUPA-targeted or nontargeted HPMA copolymer-DTX 
conjugates was determined by using HPLC after complete enzymatic hydrolysis of DTX 
from DUPA targeted or nontargeted HPMA copolymer-DTX conjugates with excess of 
papain. The general procedure to measure the DTX content in conjugate: (i) to a 1 mL of 
Eppendorf vial was added 10 µL of 20 mg/mL of DTX conjugate in DMSO solution; (ii) 
added 100 ??? ??? ??? ??? ???????????? ??? ???????????? ??????? ???? ??? ???????????? ??
phosphate pH 6.0); (iii) added 20 µL of 25 mg/mL pap?????????????????????????; (iv) the 
mixture was incubated at 37 °C for 12 h; (v) the reaction was terminated by addition of 
10 µL of 3*10-3 M sodium iodoacetate (enzyme inhibitor) solution and 280 µL of 0.02% 
of acetic acid in methanol. The amount of released DTX in the final mixture was 
measured by analytical HPLC (Agilent Technologies 1100 series, Zorbax C8 column 4.6 
X 150 mm) using gradient elution from 30% to 90% of buffer B in 30 min (Buffer A: 0.1% 
TFA in DI water; Buffer B: 0.1% TFA in acetonitrile), and the flow rate was 1.0 mL/min.  
Free DTX was used for standard curve calibration generated under the same conditions as 
the assay. 
The DUPA content in DUPA-targeted HPMA copolymer-DTX conjugates was 
determined by amino acid analysis. The general procedure for measuring DUPA content 
in DUPA targeted HPMA copolymer-DTX conjugates: (i) 2 mg of DUPA targeted 
HPMA copolymer-DTX conjugates and 0.5 mL of 6 M HCl in a sealed ampule were 
heated at 110 oC for 24 h, (ii) the solvent was removed under reduced pressure and the 
residue was redissolved in 100 µL of DI water; (iii) derivatization of hydrolyzed amino 
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acid by sequential addition: 20 µL of potassium tetraborate in distilled water (150 µg/µL), 
20 µL of o-phthaldialdehyde in methanol (50 µg/µL), 20 µL of mercaptopropionic acid in 
distilled water (0.05 mL/1 mL), 20 µL of sample solution; (iv) the mixture was vortexed 
for 1 min and was added 0.5 mL of 0.1 M sodium acetate buffer, and then filtered; (v) the 
fluorescence (Ex = 229 nm, Em = 450 nm) of the hydrolyzed amino acid derivatives was 
measured by analytical HPLC (Agilent Technologies 1100 series, XDB-C8, 5 µm, 
column 4.6 X 150 mm) using gradient elution (0-2 min, 10% buffer B; 2-10 min, 10%-50% 
buffer B; 10-20 min, 50%-60% buffer B; 20-25 min, 60% buffer B; 25-30 min, 60%-70% 
buffer B; 30-35 min, 70%-90% buffer B; 35-40 min, 90% buffer B) (Buffer A: 0.05 M 
sodium acetate in 25 mL of acetonitrile and 975 mL of DI water, pH 6; Buffer B: 0.05 M 
sodium acetate in 300 mL of DI water and 700 mL of methanol, pH 6), and the flow rate 
was 1.0 mL/min. Monomer MA-DUPA was used for standard curve calibration.  
 
2.3.7 Cell culture 
 LNCaP-derived androgen-independent C4-2 cell line was kindly provided by Dr. 
Elsässer-Beile (University of Karlsruhe). PC-3 cell line was purchased from American 
Type Culture Collection (ATCC) (Manassas, VA). Cells were maintained in RPMI-1640 
medium (Sigma-Aldrich, St. Louis, MO) supplemented with 10% (v/v) fetal bovine 
serum (FBS), 100 U/ml penicillin, and 100 µg/mL streptomycin (Gibco, Carlsbad, CA). 
Cells were incubated at 37 oC in a humidified atmosphere of 5% CO2 (v/v). Cells were 





2.3.8 PSMA cell surface expression 
 The PSMA surface expression on C4-2 and PC-3 cells was measured by flow 
cytometry. The cells were detached from flask with 0.05% of trypsin in 
ethylenediaminetetraacetic acid (EDTA), centrifuged at 1000 rpm, and washed three 
times with PBS. After cooling the cells and solutions to 4 oC, about 200,000 cells were 
re-suspended in 100 ?L staining buffer (PBS solution containing 3% FBS and 0.1 % 
NaN3). Then to each vial was added 100 ?L of 10 ?g/mL primary antibody 3F/11 
(provided by Dr. Elsässer-Beile). The final 3/F11 concentration was 5 ?g/mL. After 
being incubated for 30 min at 4 oC, the cells were washed three times with 1 mL of 
staining buffer. Following incubation with a 1:500 dilution of secondary antibody (Alexa 
Fluor 488 goat anti-mouse IgG (H+L), 4 ?g / mL) (Life Technologies, Grand Island, NY) 
at 4 oC for 30 min, the cells were washed three times with staining buffer and kept in 250 
?L of staining buffer for flow cytometry study. No-staining cells were used as the 
negative control. 
 
2.3.9 In vitro cytotoxicity 
 The cytotoxicity of DTX conjugates against C4-2 human prostate cancer cells was 
measured by Cell Counting Kit-8 assay (CCK-8, Dojindo, Japan). The C4-2 cells were 
seeded in 96-well plates at a density of 5,000 cells/well in 100 µL RMPI-1640 media 
containing 10% fetal bovine serum. After 24 h, old media were removed and replaced 
with a series concentration of DTX conjugates in 100 µL media. After 72 h, 50 µL of 1:5 
diluted original CCK-8 solution was added and incubated for 1-2 h. The absorbance of 
the reduced product formazan at 450 nm (630 nm as reference) was measured with a 
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microplate reader (Bio-Rad, Hercules, CA). The data were analyzed using GraphPad 
Prism v. 5.03 (GraphPad Software Inc., La Jolla, CA). 
 
2.3.10 Tumor models 
 All animals were handled in compliance with the Institutional Animal Care and 
Use Committee (IACUC) guidelines in University of Utah. All works were conducted 
under the protocol (#10-10006) approved by University of Utah IACUC. Male nu/nu 
mice (about 6 weeks of age) were obtained from Charles River (Wilmington, MA) and 
housed in BPRB Rm#28 with a controlled environment (24oC); 12:12-h light dark cycle) 
under specific-pathogen free conditions with water and food provided ad libitum.  In this 
study, male nu/nu mice were inoculated subcutaneously with two millions of C4-2 cells 
in 200 µL of a mixture of Matrigel/medium =1/1 in the right flank.  
 
2.3.11 In vivo anticancer efficacy of DUPA-targeted and nontargeted 
 HPMA copolymer-DTX conjugates 
 The efficacies of DTX conjugates were assessed in six groups of nu/nu mice 
bearing C4-2 prostate cancer xenografts. When the tumor volume reached approximately 
100-200 mm3, the mice were administered three dosages of 3 mg/kg DTX equivalent 
DUPA targeted and nontargeted HPMA copolymer-DTX conjugates, free DTX, and 
saline via tail vein once per week (days 0, 7, and 14). After the first dose, the mice weight 
was monitored everyday and tumor growth was monitored three times per week. The 
perpendicular diameters (length and width) of the tumors were measured by digital 
calipers, and the tumor volume was calculated by the following formula: (3.14 * Width2 * 
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Length)/6. Mice were euthanized when the tumor weight reached 10% of the predosing 
weight. Individual tumor volume relative to initial size was calculated. At study end 
points, mice were euthanized and their tumors as well as organs were excised. The 
tumors and organs were stored in 10% of formalin and embedded in paraffin, 
cryosectioned, and stained with hematoxylin and eosin (H&E) for histological analysis. 
The slices were examined with fluorescence microscope.  
 
2.3.12 Statistical analysis 
 Data values were expressed as the mean ± standard error of the mean (SEM). 
Difference between means was assessed by one-way analysis of variance (ANOVA) and 
????????? ????? ?????? ????????? ?????? ?????????? ?? ??????? ?? ????? were considered 
statistically significant. 
 
2.4. Results and Discussion 
2.4.1 Design, synthesis, and characterization of MA-GFLG-DTX 
 There are two common ways to prepare drug conjugates: one way is to prepare 
the conjugate precursor first, then attach the drug into the conjugate; the other way is to 
prepare a monomer form of drug, then copolymerize with comonomers to prepare the 
drug conjugates. Compared with the former method, the latter method has several 
advantages: (i) flexible to control the drug content by adjusting the monomer drug 
content in feed; (ii) easier to obtain the pure product when the drug has several reactive 
groups. As there are three hydroxyl groups in DTX at the C-7, C-10, and C-2? positions, 
respectively, we prefer to prepare monomer MA-GFLG-DTX first and then polymerize 
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the comonomers. The tetrapeptide (-GFLG-) was used as the spacer to conjugate the drug 
DTX into HPMA copolymer as this peptide is degraded in the lysosomes (34,36,37). 
Thus the free drug DTX will be released from the HPMA copolymer in the lysosomal 
compartment. The design and synthesis of MA-GFLG-DTX is shown in Figure 2.1. The 
monomer MA-GFLG-DTX was prepared by coupling MA-GFLG-OH with DTX at 0 oC 
in the presence of DMAP and EDC in DCM. The coupling reaction occurred 
preferentially at the C-??? ????????? ????????? ?????? ???? ??????? ?????????? ???????? ????
hydroxyl group reactivity at both C-7 and C-10 positions. Furthermore, the coupling 
reaction selectivity among those hydroxyl groups was enhanced by lowering the reaction 
temperature to 0oC.  The mass spectrum of MA-GFLG-DTX is shown in Figure 2.2. 
 
2.4.2 Design, synthesis, and characterization of polymerizable  
DUPA derivatives with different spacer lengths 
 Using similar rationale as for MA-GFLG-DTX, the targeting moiety DUPA was 
also converted to a polymerizable form. We designed and synthesized two kinds of 
DUPA monomer, MA-DUPA (Figure 2.3) and MA-EG12-DUPA (Figure 2.7). Because 
the modification at C2 position in DUPA results in minimal loss of binding affinity (28), 
the monomer forms of DUPA were prepared by conjugation at this position. To make 
sure the targeting moiety can reach the active site of PSMA, we incorporated twelve 
ethylene glycol units as a spacer between the DUPA and methacryloyl group in the 
monomer MA-EG12-DUPA. This > 47 Å spacer should be long enough to easily access 
the PSMA binding site via the funnel-shaped tunnel (30). To evaluate whether the spacer 
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length between targeting moiety and polymer drug carrier can affect the efficacy of drug 
conjugates, we prepared monomer MA-DUPA with short spacer as a control.  
The preparation of monomer (MA-DUPA) is shown in Figure 2.3. The core 
ligand, 2-[3-(1,3-bis-tert-butoxycarbonyl-propyl)-ureido] pentanedioic acid 1-tert-butyl 
ester, was synthesized according to the literature (20). It started from reaction of L-
glutamate di-tert-butyl ester hydrochloride, triphosgene, ?????-benzoylated glutamic acid 
to obtain 2-[3-(3-benzyloxycarbonyl-1-tert-butoxycarbonyl-propyl)-ureido] pentanedioic 
acid di-tert-butyl ester (Compound 4). The benzyl group was selectively removed with 
activated palladium-carbon to obtain the 2-[3-(1,3-bis-tert-butoxycarbonyl-propyl)-ureido] 
pentanedioic acid 1-tert-butyl ester (Compound 5). Then the carboxylic acid 5 was 
coupled with APMA to obtain (3S, 7S)-tri-tert-butyl-17-methyl-5,10,16-trioxo-4,6,11,15-
tetraazaoctadec-17-ene-1,3,7-tricarboxylate (Compound 7). Under acid assisted 
microwave irradiation, three tert-butyl groups in Compound 7 were removed to obtain 
monomer MA-DUPA. After being purified with RP-HPLC, the monomer MA-DUPA 
was characterized with both 1H NMR and MS (Figure 2.6). 
As shown in Figure 2.7, the preparation of monomer MA-EG12-DUPA started 
from the coupling of APMA with Fmoc-NH-EG12-COOH in the presence of HATU and 
DIPEA in DCM. After the Fmoc group in the MA-EG12-NHFmoc was removed with 20% 
piperidine in DMF, the amine 10 was coupled with carboxylic acid 5 to obtain MA-EG12-
DUPA(tri-tert-butyl). The next step is to remove the three tert-butyl groups. First, we 
tried the same reaction condition as used in the preparation of monomer MA-DUPA. 
From the mass spectrum, several water molecules were lost from the desired product. 
Then we optimized the reaction condition by lowering the reaction temperature from 
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70oC to 50 oC. After being purified with RP-HPLC, the desired product MA-EG12-DUPA 
with correct mass spectrum was obtained (Figure 2.9). 
 
2.4.3 Design, synthesis, and characterization of DUPA targeted  
and nontargeted HPMA copolymer-DTX conjugates 
 RAFT polymerization has been widely applied for preparation of drug delivery 
systems due to its unique advantages: precise control of the molecular weight of the 
product, less by-products, opportunity to synthesize telechelic polymers, and possibility 
to polymerize in aqueous environment. RAFT polymerization required all the monomers, 
initiator, and CTA to be soluble, and reaction kinetics to be reasonable. A mixture of 
DMSO and DI water was used as the solvent for these RAFT polymerizations because all 
the monomers, initiator, and CTA were soluble in DMSO, and DI water was added to 
facilitate the RAFT polymerization.  
 The DUPA targeted and nontargeted HPMA copolymer-DTX conjugates were 
prepared by RAFT polymerization of comonomers: MA-GFLG-DTX, MA-EG12-DUPA, 
and HPMA for P-DTX-EG12-DUPA; MA-GFLG-DTX, MA-DUPA, and HPMA for P-
DTX-DUPA and P-DTX-mDUPA; MA-GFLG-DTX and HPMA for P-DTX. The 
schematic structure of the DUPA targeted and nontargeted DTX drug conjugates is 
shown in Figure 2.14. For all the DTX conjugates, degradable linker is the lysosomally 
degradable tetrapeptide spacer ?-GFLG-?. For P-DTX, Z is ?????????????????????????????
moiety DUPA in this conjugate. For P-DTX-DUPA, the spacer between targeting moiety 
and polymer backbone is short, that is, three methylene groups. In P-DTX-DUPA, Z is 
















about 7.9. For P-DTX-mDUPA, the spacer between targeting moiety and polymer 
backbone is the same as that of in P-DTX-DUPA. The difference is that there are more 
targeting moieties (Z = ?26.5) in P-DTX-mDUPA polymer chain. For P-DTX-EG12-
DUPA, the spacer between targeting moiety and polymer backbone is long, including 
five methylene groups and twelve ethylene glycol groups. In P-DTX-EG12-DUPA, Z is 
??????, that means there are about 4.8 targeting moieties in one polymer chain. Figure 
2.13 shows the structure and synthetic scheme of P-DTX-EG12-DUPA. CPAD and V-65 
were used as the CTA and initiator, respectively. The structure, synthetic scheme, and 
SEC profile of P-DTX, P-DTX-DUPA, and P-DTX-mDUPA are shown in Figures 2.10, 
2.11, and 2.12, respectively. Table 2.1 summarizes the molecular weights, 
polydispersities, DTX and DUPA content in DUPA-targeted and nontargeted HPMA 
copolymer-DTX conjugates. The molecular weights of all polymer conjugates are well 
controlled with low polydispersities.  
 
2.4.4 In vitro cytotoxicity 
 To check whether the C4-2 cell lines are PSMA positive, C4-2 prostate cancer 
cells and the negative control PC-3 prostate cancer cells were successively incubated with 
primary mouse anti-PSMA human antibody and secondary goat anti-mouse IgG (H+L) 
antibody with Alexa Fluor 488. Then those cells were analyzed by flow cytometry. 
Unstained cells were used as the control. In Figure 2.15, the red line indicates the 
unstained cells and the blue line indicates the stained cells. The flow cytometry results 
show that PSMA are expressed on C4-2 cells but not on PC-3. After confirmation of the 









Table 2.1 Physicochemical properties of DUPA-targeted  




















Figure 2.15: PSMA expression on C4-2 and PC-3 cell surface. The red line shows the 
unstained cells. The blue line shows the cells that had been stained with primary anti-












DUPA targeted and nontargeted HPMA copolymer-DTX conjugates toward C4-2 human 
prostate cancer cells. As shown in Table 2.2, P-DTX, P-DTX-DUPA, P-DTX-mDUPA, 
and P-DTX-EG12-DUPA all possess strong cytotoxicity toward C4-2 cells (IC50 = 
4.14±1.03 nM, 2.99±1.09 nM, 3.32±1.00 nM, 3.18±0.42 nM, respectively. The data are 
presented as mean ± SEM. n = 3.). The similar IC50 doses can be explained by the 
presence of ester bond between DTX and HPMA copolymer backbone; part of the DTX 
was released from the conjugates during 72 h incubation in cell culture media. 
Consequently, C4-2 cells were exposed to a mixture of free and polymer-bound DTX. 
This is consistent with another ???????????????????????????????(38). 
 
2.4.5 In vivo efficacy 
 Among prostate cancer tumor models, the C4-2 tumor model mimics closely 
human prostate cancer growth (39). Therefore, the antitumor activities of DUPA-targeted 
and nontargeted HPMA copolymer-DTX conjugates were tested in six groups of nu/nu 
mice bearing C4-2 prostate cancer xenografts (n = 4-6): untreated control (saline), free 
DTX, nontargeted conjugate (P-DTX), and DUPA-targeted conjugates (P-DTX-DUPA, 
P-DTX-mDUPA, and P-DTX-EG12-DUPA). Based on preliminary experiments, dosage 
(3 mg/kg) was enough to control C4-2 tumor growth (unpublished data). Three doses of 3 
mg/kg DTX equivalent were administered via tail vein once per week (days 0, 7, and 14). 
At study end points, mice were euthanized and their tumors as well as organs were 
excised. As shown in Figure 2.16.A, the targeted DTX conjugate with longer spacer (P-
DTX-EG12-DUPA) was significantly more efficacious in tumor size reduction than P-










Table 2.2 IC50 of DUPA-targeted or nontargeted DTX 

















tumors at the end points for DTX conjugates treated groups are shown in Figure 2.16.B. 
For the treated group of P-DTX, P-DTX-mDUPA, and P-DTX-EG12-DUPA at day 42 
after the first treatment, the mean relative tumor percents ((final tumor size/initial 
size)*100) were (1590 ? 208)%, (1193 ? 285)%, and (810 ? 160)%, respectively (mean ? 
SEM). Consistent with our hypothesis that the spacer length is important for DUPA 
attachment to the PSMA binding site, the efficacy of P-DTX-EG12-DUPA was the 
highest of all conjugates studied; there was no significant difference in the efficacy of P-
DTX, P-DTX-DUPA, and P-DTX-mDUPA. Interestingly, the P-DTX-mDUPA 
possessed lesser efficacy than that P-DTX at early stages, but more efficacy in later 
stages of the experiment although the difference is not statistically significant. 
 
2.4.6 Adverse effects 
 To evaluate whether the DUPA-targeted or nontargeted DTX conjugates have 
nonspecific toxicities, the weight of treated and nontreated mice was monitored everyday. 
As shown in Figure 2.17, both treated and nontreated mice exhibited a slight weight loss 
maybe due to the bearing of tumor. However, there was no significant difference between 
treated and nontreated mice groups.  
To further test whether the DTX conjugates have toxicity or not, we analyzed the 
histology of major organs (heart, liver, spleen, kidney, lung) after the mice were 
sacrificed. As shown in Figure 2.18, histologic examination of H&E stained sections 
from paraffin embedded tissue of organs in treated and nontreated groups indicated no 
pathologic changes or end organ damage. Histologic sections from the heart and liver 







Figure 2.16: In vivo antitumor activity of DUPA-targeted or nontargeted HPMA 
copolymer-DTX conjugates in nude mice bearing s.c. C4-2 prostate cancer xenografts. (A) 
C4-2 tumor growth curve after treatment with three doses of DTX, P-DTX, P-DTX-
DUPA, P-DTX-mDUPA, and P-DTX-EG12-DUPA (3 mg equivalent DTX/kg at days 0, 7, 
and 14). Control mice were administered saline. The data are presented as mean ± SEM 
(n =4-6; *P<0.05; ns, not significant). (B) Images of excised tumors from mice, which 
were treated by P-DTX, P-DTX-mDUPA, and P-DTX-EG12-DUPA, respectively. Those 







Figure 2.17: Percentage of mean body weight change of nu/nu mice bearing s.c. C4-2 
prostate cancer xenografts following administration of saline, DTX, P-DTX, P-DTX-
DUPA, P-DTX-mDUPA, and P-DTX-EG12-DUPA (3 mg equivalent DTX/kg at days 0, 7, 















Figure 2.18:  Histology images of major organs (heart, liver, spleen, kidney, lung)  




control samples. White and red bulb of the spleen also did not show histopathologic 
differences. Similarly section of the kidney showed normal glomeruli without evidence of 
tubular necrosis in any of the groups. Compared to the control group, there was no 
significant histologic difference in the lung tissue from the treated group.   
 
2.5 Conclusion 
 In summary, we examined the targeting effect of DUPA and the spacer length 
effect in the treatment of PSMA expressing prostate cancer. Two polymerizable forms of 
DUPA with different spacer length were prepared and characterized. DUPA targeted and 
nontargeted HPMA copolymer - DTX conjugates with well-controlled molecular weight 
and molecular weight distribution were efficiently prepared by RAFT polymerization. To 
our knowledge, this is the first time to directly incorporate the targeting moiety DUPA 
into drug delivery system by polymerization. Importantly, the general approach to 
prepare monomer form of DUPA can be extended to a wide variety of other PSMA 
targeting moieties such as phosphoramidates and peptides. Importantly, the P-DTX-
mDUPA and P-DTX-EG12-DUPA treated groups exhibited better tumor regression than 
that of the P-DTX treated group at the study end point. This might be attributed to the 
targeting effect of DUPA toward PSMA on tumor cells. Furthermore, P-DTX-EG12-
DUPA exhibited better C4-2 tumor regression than that of P-DTX-mDUPA even though 
the P-DTX-mDUPA contains more targeting moieties than P-DTX-EG12-DUPA. These 
in vivo results show that the spacer length between targeting moieties and HPMA 
copolymer backbone affects ???? ??????? ?????????? ???????? and concomitantly the 
treatment efficacy of DTX conjugates against C4-2 tumor bearing nu/nu mice. However, 
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it is also possible that the enhanced treatment effect of P-DTX-EG12-DUPA result from 
other factors such as the change of morphology and enhanced water solubility of 
conjugates. Moreover, histology study showed that the DUPA-targeted DTX conjugate 
exhibited no nonspecific toxicity to the treated mice. This formulation design provides a 
promising targeted therapeutics for PSMA expressing prostate cancer treatment. The 
results of this study demonstrated the importance of spacer length in targeted drug 
delivery, especially when the size of targeting moiety is small. Further modifications, 
such as optimizing the targeting moieties distribution and increasing the number of 
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SYNTHESIS AND ACTIVITIES OF TUMOR-HOMING PEPTIDE iRGD AND 
HISTONE DEACETYLASE INHIBITOR VALPROIC ACID CONJUGATE1 
 
3.1 Summary 
   In  this  chapter,  we  present  a  concise  strategy  to  prepare  a  conjugate  of  the  tumor-­  
homing   peptide   iRGD   and   histone   deacetylase   inhibitor   Valproic   acid   (VPA),   VPA-­
GFLG-­iRGD.  Conjugates  VPA-­GFLG-­iRGD  and  GFLG-­iRGD  were  prepared  by  solid  
phase   synthesis.  The   activities   of  VPA-­GFLG-­iRGD  and   related   controls   against  DU-­
145   prostate   cancer   cells   were   tested   by   both   cell   cytotoxicity   and   cell   cycle   arrest  
assays.  The  conjugate  VPA-­GFLG-­iRGD  and  a  mixture  of  VPA  and  GFLG-­iRGD  have  
shown  similar  cytotoxicity  against  DU-­145  prostate  cancer  cells.  However,  the  treatment  
of  DU-­145  cells  with  conjugate  VPA-­GFLG-­iRGD  resulted  in  a  decreased  percentage  of  
cells  in  the  G2  phase,  whereas  the  exposure  of  a  mixture  of  VPA  and  GFLG-­iRGD  led  
to   an   increased  percentage  of   cells   in   the  G2  phase.  We  also   found   that  GFLG-­iRGD  
possessed  cytotoxicity  at  the  tested  concentrations.    
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  This chapter has been modified with permission from the following the publication: 
Peng ZH, ?????????. Synthesis  and  activity  of  tumor-­homing  peptide  iRGD  and  histone  





 Epigenetic therapy has shown promise in the treatment of cancer (1). 
Manipulation of the histone acetylation by histone acetyltransferases (HATs) and 
histone deacetylases (HDACs) regulate epigenetics gene expression. HDACs catalyze 
the removal of acetyl groups from amino terminal lysine residue in histones; the 
resulting ionic interactions between the positively charged histones and the negatively 
charged DNA induce transcriptional repression through chromatin condensation (2?5). 
HDACs activities in prostate cancer cell lines are two to three folds higher than that in 
benign prostatic hyperplasia (BPH) cell line (6,7). HDAC isoforms are strongly 
expressed in majority of the prostate carcinomas (HDAC1: 69.8%, HDAC2: 74%, 
HDAC3: 94.8%) (8). In the last decade, HDAC inhibitors (HDACi) have shown promise 
in the treatment of cancers, including prostate cancer. As shown in Figure 3.1, HDCAi 
are classified into four subtypes: hydroxamate, cyclic peptide, short-chain fatty acid, and 
benzamide (9). HDACi have shown promising in antiproliferative and apoptotic 
properties on various cancer cells, including prostate cancer cells (10). Vorinostat and 
romidepsin have been approved by United States Food and Drug Administration for 
treating cutaneous and peripheral T-cell lymphoma, respectively, and several HDACi 
have entered clinical trial. However, HDACi are not satisfactory for solid tumor 
treatment. For example, Vorinostat has significant toxicities in clinical trial in patients 
with metastatic castration resistant prostate cancer (11,12). Targeting strategies have 





















 Valproic acid (VPA, 2-propylpentanoic acid) is a short-chain branched fatty acid, 
which has been used as an anticonvulsant for more than four decades. Now VPA has 
shown promise for inhibiting tumor growth and metastasis. VPA inhibits HDACs and 
causes histone hyperacetylation at therapeutic concentrations (14,15). VPA selectively 
decreases HDAC expression in human ovarian cancer cells, causes tumor cell growth 
arrest, and inhibits HeLa cervical cancer cell growth (14?18). The combination of VPA 
with other drugs has enhanced anticancer effect. Specifically, its combination with 
cyclin-dependent kinase (CDK) inhibitor is effective in treatment of lung tumor 
xenograft in SCID mice (19). In addition, VPA and Aspirin have synergistic cytotoxicity 
against hepatocellular cancer cells (20). Aurora Kinase Inhibitors can also enhance the 
cytotoxicity of VPA against gynecologic cancer cells (21). VPA enhanced the sensitivity 
of anaplastic thyroid cancer cells toward doxorubicin (22). Exposure to VPA enhanced 
the radiosensitivity of prostate cancer (23). Chronic administration of VPA caused the 
increase of acetylation of histone H3, cancer cell cycle arrest, and reduction of tumor 
xenograft (24,25). Furthermore, VPA has the potential to inhibit prostate cancer 
metastasis by inhibiting prostate cancer migration through up-regulating E-cadherin 
expression (26).  
 Protein transduction domains (PTDs) or cell-penetrating peptides (CPPs) are 
often attached to therapeutics to enhance their cellular uptake (27,28). However, most 
CPPs cause undesired toxicities because they cannot distinguish between normal and 
???????????????????????????????????????????????????????????????????????????????????????????
effects in normal cells (29?32). Targeting moieties have been also attached to CPPs or 
CPP conjugates to improve CPP?s selectivity (33,34). Recently, Ruoslahti and 
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coworkers discovered that a specific tumor-homing peptide iRGD, which combines a 
targeting peptide and a cell-penetrating peptide, can significantly improve drug uptake 
into specific tumors (35,36). 
In this study, we designed, prepared and tested a novel drug conjugate VPA-
GFLG-iRGD. The structure of VPA-GFLG-iRGD is composed of three components 
(Figure 3.2.A): cell-penetrating peptide iRGD, VPA, and lysosomally degradable 
tetrapeptide (-GFLG-) spacer. The RGD sequence in the VPA-GFLG-iRGD will 
recognize the integrin receptor on the prostate cancer cell surface. The RGD-integrin 
interaction will assist the uptake of conjugate VPA-GFLG-iRGD into prostate cancer 
cells. 
 
3.3 Materials and Methods 
3.3.1 Materials 
 Protected amino acids and Rink amide MBHA resin were purchased from 
AAPPTEC (Louisville, KY). 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-
b]pyridinium 3-oxid hexafluorophosphate (HATU) was purchased from P3bioSystems 
(Shelbyville, KY). Thallium (III) trifluoroacetate (Tl(OOCF3)3), piperidine, N-
methylmorpholine (NMM), and triisopropylsilane (TIPS) were purchased from Sigma 
Aldrich (St. Louis, MO). Tris(2-carboxyethyl) phosphine hydrochloride (TCEP) was 
purchased from Thermo Scientific (Waltham, MA). Dimethylformamide (DMF), 
acetonitrile (ACN) and methanol were purchased from Fisher Scientific (Fair Lawn, NJ). 












Figure 3.2: Chemical structure of VPA-GFLG-iRGD (A), 











3.3.2 Synthesis of VPA-GFLG-iRGD and GFLG-iRGD 
 As shown in Figure 3.3, the conjugate VPA-GFLG-iRGD was prepared by solid 
phase synthesis. The first step was to prepare the linear conjugate VPA-Gly-Phe-Leu-
Gly-Cys(Acm)-Arg(Pbf)-Gly-Asp(OBut)-Lys(Boc)-Gly-Pro-Asp(OBut)-Cys(Acm) on 
the MBHA Rink amide resin (37). The general procedure for stepwise attachment of 
each protected amino acid (Fmoc-Cys(Acm)-OH, Fmoc-Asp(OBut)-OH, Fmoc-Pro-OH, 
Fmoc-Gly-OH, Fmoc-Lys(Boc)-OH, Fmoc-Asp(OBut)-OH, Fmoc-Gly-OH, Fmoc-
Arg(Pbf)-OH, Fmoc-Cys(Acm)-OH, Fmoc-Gly-OH, Fmoc-Leu-OH, Fmoc-Phe-OH, 
Fmoc-Gly-OH) (468 µmol), and VPA (468 µmol) on MBHA Rink amide resin (300 mg, 
156 µmol) includes two parts: (i) 20% of piperidine in DMF was mixed with resin for 5 
min to remove Fmoc protecting group; (ii) the Fmoc protected amino acid or VPA was 
dissolved in a mixture of 0.4 mM N-methylmorpholine (NMM) and DMF then 
incubated with the resin for 20 min at room temperature. 1-
[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluoro 
phosphate (HATU) was used as the coupling agent. 
 The second step was to cyclize the iRGD peptide via a disulfide bridge by 
treating the resin bound peptide with a solution of Tl(OOCCF3)3 in DMF (38). Finally, 
the peptide conjugate was cleaved from the resin by using a mixture of H2O/TIPS/TFA 
= 2.5/2.5/95. Other acid labile protecting groups (But on Asp, Boc on Lys, and Pbf on 
Arg) were also removed during the cleavage process.  
 The preparation of GFLG-iRGD is similar as that of VPA-GFLG-iRGD except 


















3.3.3 Purification and characterization of GFLG-iRGD and VPA-GFLG-iRGD 
 Both conjugates were purified by RP-HPLC (Agilent 1100 series) equipped with 
a semipreparative ZORBAX 300SB-C18 column (5 µm, 9.4*250 mm) from Agilent 
Technologies (Santa Clara, CA). The purity of conjugates were checked with analytical 
ZORBAX 300SB-C18 column (5 µm, 4.6*250 mm) in the same instrument as used for 
purification. Two buffers were used as elution agents: buffer A (0.1% TFA in DI water), 
buffer B (0.1% TFA in acetonitrile). The structures of these two conjugates were 
measured by MALDI-TOF mass spectrometry (Voyager-DE STR Biospectromety 
Workstation, Perseptive Biosystems, Framingham, MA).  
 
3.3.4 Reduction of VPA-GFLG-iRGD 
 The reduction scheme of VPA-GFLG-iRGD is shown in Figure 3.4. To a vial 
was added 0.2 mg of conjugate VPA-GFLG-iRGD and 0.5 mL of 10 mM TCEP in 10 
mM PBS buffer with 1 mM EDTA. The mixture solution was incubated at 37 oC for 2 h. 
The reduced product was analyzed with MALDI-TOF mass spectrometry (Voyager-DE 
STR Biospectromety Workstation, Perseptive Biosystems, Framingham, MA). 
 
3.3.5 Cell culture 
DU-145 prostate cancer cells (ATCC, Manassas, VA) were grown in RPMI-1640 
media (Sigma-Aldrich, St. Louis, MO) supplemented with 10% (v/v) FBS, 100 U/ml 
???????????????????????????????????????????????????????????????????oC in a humidified 















3.3.6 Induction of DU-145 cell cycle arrest by VPA-GFLG-iRGD,  
VPA, GFLG-iRGD or a mixture of VPA and GFLG-iRGD 
 In the cell cycle arrest experiments, the following steps were performed: (I) DU-
145 cells were seeded at a density of 5*105cells/well in 6-well plates for 24 h; (II) the 
media was replaced with 1.5 mM of VPA, GFLG-iRGD, VPA-GFLG-iRGD, or a 
mixture of VPA and GFLG-iRGD, then incubated for another 24 h; (III) the media was 
removed, and the cells were washed with PBS; (IV) the cells were detached from 6-well 
plates, and transferred to 1.5 mL Eppendorf vials; (V) after removing the supernatant, 
the cells were resuspended in 100 µL PBS; (VI) added 400 µL of ice cold 100% ethanol 
to each vial and kept at room temperature for 2 h; (VII) added 1 mL of PBS to cells and 
spun for 5 min, then aspirated and washed with 1 mL PBS; (VIII) resuspended cells in 
500 µL of propidium iodide (PI) staining solution (50 µg/mL PI, 200 µg/mL RNase); 
(IX) covered with foil and analyzed on flow cytometer. The cell cycle arrest assay was 
repeated four times. 
 
3.3.7 Cytotoxicity of VPA-GFLG-iRGD, VPA, GFLG-iRGD or a  
mixture of VPA and GFLG-iRGD 
The DU-145 cells were seeded in 96-well plates at a density of 3,500 cell/well in 
100 ???????-1640 media containing 10% fetal bovine serum. After incubating at 37 oC 
for 24 h, media was removed and replaced with 1.5 mM of VPA, GFLG-iRGD, VPA 
plus GFLG-iRGD or VPA-GFLG-iRGD. After incubation at 37 oC for ???????????????
1:5 diluted original Cell Counting Kit-8 (CCK-8) (Dojindo, Japan) solution was added 
and incubated at 37 oC for 1-2 h. The absorbance of the reduced product formazan at 
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450 nm (630 nm as reference) was measured with a microplate reader (Bio-Rad, 
Hercules, CA). The data were analyzed with One-????????????????????????????-hoc 
test by using Prism 5 software.  
 
3.4 Results and Discussion 
3.4.1 Synthesis and characterization of VPA-GFLG-iRGD and GFLG-iRGD 
 The structure of the VPA-GFLG-iRGD conjugate was confirmed by MALDI-
TOF (matrix-assisted laser desorption ionization, time-of-flight) mass spectroscopy. As 
shown in Figure 3.5, the peaks at m/z 1447.69 correspond to the desired product 
([M+H]+). The elution time of VPA-GFLG-iRGD and its reduced product on an HPLC 
analytical column (Agilent, 300SB-C18, 4.6 * 250 mm, 5 ????????????????????????? ????
respectively, when using a gradient solvent from 10% Buffer B to 100% Buffer B in 30 
min (Buffer A and Buffer B are the same as used in Section 3.3.3). The reduction of the 
disulfide bond produced two sulfhydryl groups, which should result in a mass 2 Da 
higher than the original VPA-GFLG-iRGD. As shown in Figure 3.6, the peak at m/z 
(MALDI-TOF) 1449.56 corresponds to the reduced product [M1+H]+. Mass spectrum 
peaks [M1+Na]+ and [M1+K]+ at m/z 1471.54 and 1487.49, respectively, support the 
structure of the reduced product. 
 
3.4.2 Induction of cell cycle arrest by VPA-GFLG-iRGD and controls 
 Representative cell cycle arrest results are shown in Figure 3.7, and the average 
cell cycle arrest results are shown in Figure 3.8. The treatment with VPA-GFLG-iRGD 


















Figure 3.7: Representative  flow  cytometric  pictures  and  percentages  of  cells  in  G1  and  
G2  phase  of  the  DU-­145  cell  cycle:  (A)  control,  (B)  1.5  mM  VPA,  (C)  1.5  mM  GFLG-­






Figure 3.8: Average  percentage  of  cells  in  G1  (A)  and  G2  (B)  phase  of  the  DU-­145  cell  
cycle.   Statistics:  One  Way  ANOVA  plus  ????????? ????-­hoc   test   (0.001<P<0.01   =   **;;  






distribution of DU-145 cells in G1 and G2 phase. The treatment with conjugate VPA-
GFLG-iRGD resulted in a decreased percentage of DU-145 cells in the G2 phase, 
whereas the exposure of cells to a mixture of VPA and GFLG-iRGD led to an increased 
percentage of cells in the G2 phase. The decreased G2 phase cell population in VPA-
GFLG-?????????????????????????????????????????????????????????????3 ???????5 on the 
DU-145 cell surface by RGD (39). 
 
3.4.3 Cell cytotoxicity of VPA-GFLG-iRGD and related controls  
against DU-145 
 The average viable cell number in untreated group was set as 100%. The 
viability % was calculated by dividing the viable cell number in the treated group by the 
average viable cell number in the untreated group. The results are expressed as (mean ± 
SEM) %. The results after treatment with 0.5 mM drug or drug equivalents are shown in 
Figure 3.9.A: control (99.97 ± 0.84), VPA (99.56 ± 7.46), GFLG-iRGD (70.52 ± 2.89), 
GFLG-iRGD + VPA (57.87 ± 6.01), VPA-GFLG-iRGD (69.30 ± 0.30). Figure 3.9.B 
shows the results after exposure to 1.5 mM drug or drug equivalent: control (100.00 ± 
2.47), VPA (79.87 ± 2.44), GFLG-iRGD (58.67 ± 3.89), GFLG-iRGD + VPA (31.22 ± 
1.33), VPA-GFLG-iRGD (38.96 ± 2.76). As shown in Figure 3.9.B, VPA-GFLG-iRGD 
was significantly more toxic than either VPA or GFLG-iRGD. Although the 
combination of VPA and GFLG-iRGD seems to possess a slightly higher toxicity than 
VPA-GFLG-iRGD, the difference is not statistically significant. Interestingly, we found 
that GFLG-iRGD has cytotoxicity to DU-145 cells at the two concentrations used. The 








Figure 3.9: Cytotoxicity of VPA, GFLG-iRGD, VPA-GFLG-iRGD, and a mixture of 
VPA and GFLG-iRGD against DU-145 prostate cancer cells: (A) 0.5 mM; (B) 1.5 mM. 
???????????? ???? ???? ?????? ????? ????????? ????-hoc test (P<0.001 = ***; 











cell surface by RGD (40). This blockage could cause the inhibition of integrin-linked 
kinase activity and phosphorylation of PKB/Akt on serin-473, which inhibited the cell 
proliferation [39]. The data were analyzed with One-????????????????????????????-
hoc test by using Prism 5 GraphPad software. 
 
3.5 Conclusion 
 In summary, we have successfully prepared a tumor cell penetrating peptide 
iRGD targeted HDAC inhibitor conjugate (VPA-GFLG-iRGD). The conjugate structure 
was confirmed by both mass spectrometry of cyclized construct and of its reduced 
product. This synthesis methodology will help to design other iRGD or other cyclic 
peptide targeted pro-drugs. The cytotoxicity of VPA toward prostate cancer cells was 
enhanced both by covalent attachment or mixture with iRGD. Both forms of VPA 
changed the stage of cell cycle arrest: the VPA-GFLG-iRGD conjugate induced the 
decreased DU-145 cell population in G2 phase, and the combination of VPA and GFLG-
iRGD enhanced G2 cell cycle arrest in DU-145 cells. We also found that the iRGD 
derivative has some cytotoxicity at the tested concentrations. The exact iRGD uptake 
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TUMOR-PENETRATING PEPTIDE TARGETED HPMA COPOLYMER 
DOXORUBICIN CONJUGATES FOR PROSTATE 
 CANCER TREATMENT 
 
4.1 Summary 
 On-demand drug release systems are important for improving the efficacy and 
reducing the side effect of drugs. Here, we describe the design, preparation, and 
biological properties of stimuli-responsive HPMA copolymer drug and tumor-penetrating 
peptide conjugates. Doxorubicin (DOX) was conjugated to HPMA copolymer via a 
lysosomally cleavable tetrapeptide spacer (-GFLG-). Tumor-homing and penetrating 
peptide iRGD was connected to HPMA copolymer through a matrix metalloproteinase 2 
(MMP-2) degradable linker (-PLGLAG-). Free iRGD and monomer MA-GG-PLGLAG-
iRGD were prepared with solid phase synthesis. HPMA copolymer-DOX conjugates (P-
DOX and P-DOX-PLGLAG-iRGD) were prepared via traditional copolymerization. The 
uptake of DOX conjugates was tested in both monolayer and multilayer DU-145 prostate 
cancer cells with flow cytometry. The results have shown that P-DOX-PLGLAG-iRGD 
treated cells had the strongest fluorescence intensity compared to that of other treated 
groups (Control, iRGD, P-DOX, P-DOX plus iRGD). The cell cycle arrest, in vitro 
apoptosis, and cytotoxicity of DOX conjugates and related controls were tested against 
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DU-145 monolayer prostate cancer cells. Consistent with the drug uptake results, the in 
vitro results show that P-DOX-PLGLAG-iRGD had the strongest activity against DU-
145 prostate cancer cells. The penetration ability of DOX conjugates was tested in 3D 
multicellular tumor cell spheroids. The results show that the conjugate P-DOX-
PLGLAG-iRGD penetrated deepest in tumor cell spheroids. 
 
4.2 Introduction 
 Nanomedicines are promising in cancer treatment due to their ability to improve 
the pharmacokinetics and efficacy as well as reduce the side effects of free drugs (1?3). 
However, more and more researchers question the low translation efficiency of 
nanomedicines from publications to drugs (4?6). One of the major reasons is that more 
than 95% of the nanomedicine accumulates in undesired organs (4). Most large molecular 
weight nanomedicines rely on enhanced permeability and retention (EPR) effect to enter 
into tumor area, but EPR effect is often compromised by the tumor microenvironment 
(7,8). The increased interstitial fluid pressure (IFP), dense stromal cells, and extracellular 
matrix (ECM) hamper the convection of nanomedicine into the tumor (9). Furthermore, 
the EPR effect is usually over-estimated by ignoring the heterogeneity within and 
between tumor types, and the variance between patients (10,11). Even in a single tumor, 
the vessel structure difference between regions results in varying degrees of EPR effect 
(10,11). The inefficiency and heterogeneity of the EPR effect may be responsible for the 
lack of overall survival benefit from nanomedicines as compared to their small molecule 
drug counterparts (10,11). Another important reason for the inefficiency of 
nanomedicines is that they cannot cross more than one or two cell layers because of their 
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large size, the high IFP, and the tight structure of tumor (12?16). Therefore, there are two 
potential ways to promote the translation of nanomedicines from research to the clinic. 
The first method is to increase the accumulation of nanomedicines in tumors and to 
facilitate the internalization of nanomedicines into tumor cells by attaching targeting 
moieties on drug carriers (17). The second method is to enhance the tumor penetration 
ability of nanomedicines by conjugation with cell-penetrating peptides (CPPs) (7,18).  
 The newly developed internalizing C-end cyclic peptide iRGD can function as 
both a tumor-homing and penetrating peptide (19,20). Although iRGD significantly 
enhanced the cell uptake of different size drugs, the short half life (a few minutes) of free 
iRGD limits its clinical application because it is cleared from the bloodstream quickly 
due to proteolysis and rapid renal clearance (21,22). Since the size of iRGD (mass 5 kDa) 
is much smaller than the pore size of glomeruli (diameter, 8 nm), iRGD can be ultra-
filtrated by the kidney completely in a few minutes (21). Conjugation to larger polymers 
or plasma proteins (albumin and immunoglobulin) are two general strategies to prolong 
the half life of peptide drugs (21). However, both our and other ??????????????????????????
the conjugated form of iRGD may lose its cell penetration/targeting ability as compared 
to its free form (20). Therefore, we aimed to develop a smart drug delivery system that 
can prolong the half-life of iRGD as well as preserve its penetration ability. The aim of 
the study in Chapter 3 was to utilize the targeting effect of iRGD by conjugating iRGD to 
valproic acid via a tetrapeptide spacer (-GFLG-). A ?GFLG- spacer was used so that the 
drug would be released in the lysosome after the drug conjugate was endocytosed into the 
tumor cells. The aim of this chapter was to enhance the penetration ability of drugs, so 
iRGD was required to be released in the tumor microenviroment to regain its penetration 
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ability. Thus, iRGD was conjugated to a drug delivery system via a tumor 
microenvironment sensitive spacer in this study.  
 As shown in Figure 4.1, we designed a MMP-2 stimuli-responsive drug delivery 
system for treatment of prostate cancer. N-(2-hydroxypropyl)methacrylamide (HPMA) 
was used as the drug carrier backbone because it is water soluble and biocompatible 
(2,3). Doxorubicin (DOX) was selected as the model drug for two major reasons: first, 
the fluorescence of DOX will make it easy to track its fate; second, DOX is one of the 
most effective anticancer drug but it has only limited penetration in prostate cancer (23). 
DOX was conjugated to HPMA copolymer via a well-defined lysosomally cleavable 
linker (-glycylphenylalanylleucylglycine-, -GFLG-) to limit nonspecific cytotoxicity 
because the drug is only released from the conjugate after the conjugates are uptaken into 
cells (24). We conjugated iRGD to HPMA copolymer via a -PLGLAG- peptide spacer, 
which was able to be cleaved by MMP-2 in the tumor microenvironment (25,26). MMP-2 
was selected as the cleavage enzyme because the expression of MMP-2 is associated with 
the growth and progression of prostate cancer (27?29). More importantly, MMP-2 is an 
effective enzyme for peptide substrate cleavage, and the ratio of kcat/Km was between 1.4 
x 104 M-1S-1 and 2 x 105 M-1S-1 (30). This strategy has at least three potential advantages. 
First, the conjugation of iRGD to the HPMA copolymer-drug conjugate actively delivers 
the drug to the tumor, thus enhancing the accumulation of drug conjugates at the tumor 
site. Second, the large molecular weight of HPMA copolymer iRGD conjugate increases 
the half-life of iRGD, thus resulting in increased opportunity to interact with integrin on 
tumor vessel endothelial cells and tumor cells. This also enhances the accumulation of 
drug conjugates in the tumor. Third, the penetration ability of free iRGD will be regained  
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after the iRGD is released from the HPMA copolymer conjugate in the tumor 
microenvironment. We hypothesized that the smart iRGD release system will improve 
the effect of DOX conjugates via the enhanced targeting and penetration effect.  
 The uptake, penetration, and accumulation of DOX conjugates were tested in DU-
145 prostate cancer cell monolayers, multicellular spheroids, and xenograft tumors. The 
activities of DOX conjugates were evaluated and compared by measuring cell apoptosis 
and viability. 
 
4.3 Material and Methods 
4.3.1 Materials 
 Doxorubicin hydrochloride was a kind gift from Meiji Seika Kaisha Ltd. (Tokyo, 
Japan). 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate (HATU), protected amino acids, and 2-chlorotrytyl chloride resin 
were purchased from AAPPTEC (Louisville, KY). 2,??-Azobis(2,4-dimethyl valeronitrile 
(V-65) was purchased from Wako (Japan). Thallium (III) trifluoroacetate (Tl(OOCF3)3), 
N-methylmorpholine (NMM), triisopropylsilane (TIPS), N,N-diisopropylethylamine 
(DIPEA), and piperidine were purchased from Sigma Aldrich (St. Louis, MO). Tris(2-
carboxyethyl) phosphine hydrochloride (TCEP) was purchased from Thermo Scientific 
(Waltham, MA). General solvents were purchased from Fisher Scientific (Fair Lawn, NJ). 
Trifluoroacetic acid (TFA) was purchased from Acros (Fair Lawn, NJ). Monomers 
HPMA (31), MA-GFLG-OH (32), and MA-GG-OH (33) were prepared as described in 
literature.  
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4.3.2 Synthesis of monomer MA-GFLG-DOX 
 The synthesis of monomer MA-GFLG-DOX is shown in Figure 4.2. Doxorubicin 
hydrochloride (1.16 g, 2 mmol), MA-GFLG-OH (875 mg, 1.9 mmol), NMM (660 ?L, 7.1 
mmol), DMF (40 mL), and a stirrer bar were added to a 100 mL of round-bottom flask. 
After the mixture was cooled to -20 oC, a solution of HATU (760 mg, 2 mmol) in DMF 
was added slowly into the mixture. The reaction temperature was kept at -20 oC for 4 h, 
then slowly increased to room temperature and kept at room temperature for another 20 h.  
After removing DMF under reduced pressure, the crude product was dissolved in 
methanol and purified with an LH-20 column. Monomer MA-GFLG-DOX (1.37g, 73%) 
was obtained after removing the methanol under vacuum. 
 
4.3.3 Preparation of monomer MA-GG-PLGLAG-iRGD and free iRGD 
The preparation of monomer MA-GG-PLGLAG-iRGD is shown in Figure 4.3. 
The synthesis of MA-GG-PLGLAG-iRGD started from manual attachment of the Fmoc-
Cys(Acm)-OH to resin by mixing 2-chlorotrityl chloride resin (400 mg, 1.1 mmol/g, 100-
200 mesh) with Fmoc-Cys(Acm)-OH (200 µmol, 117 mg) at room temperature for 2 h. 
The remaining active groups in resin were capped with a mixture solution of 
dichloromethane (DCM) : methanol (MeOH) : DIPEA = 17 : 2 : 1.  
Next, protected amino acids (Fmoc-Asp(OtBu)-OH, Fmoc-Pro-OH, Fmoc-Gly-
OH, Fmoc-Lys(Boc)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Gly-OH, Fmoc-Arg(Pbf)-OH, 
Fmoc-Cys(Acm)-OH, Fmoc-Gly-OH, Fmoc-Ala-OH, Fmoc-Leu-OH, Fmoc-Gly-OH, 
Fmoc-Leu-OH, Fmoc-Pro-OH), or MA-GG-OH were loaded to resin sequentially with 
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coupling steps: (i) the Fmoc protecting groups were removed by mixing resin bound 
peptide with 20% piperidine in DMF for 5 min; (ii) the coupling reaction was conducted 
by mixing three equivalents (600 µmol) of protected amino acid (Fmoc-AA(XXX)-OH) 
or MA-GG-OH with resin bound peptide in the presence of HATU (228 mg, 600 µmol).   
 Then, a solution of thallium trifluoroacetate (Tl(OOCF3)3) (254 mg, 468 µmol) in 
DMF was added to the resin bound linear peptide and the mixture kept at room 
temperature under shaking. The Tl(OOCF3)3 solution was removed by filtration, and the 
remaining resin was washed with DMF and MeOH, respectively, for three times.  
 Finally, the crude product MA-GG-PLGLAG-iRGD was obtained by mixing the 
dried resin bound peptide with 10 mL of cleavage solution (TFA/TIPS/H2O = 95/2.5/2.5) 
for 3 h. After removing most of the solvent under vacuum, the remaining residue was 
added into cold diethyl ether to precipitate the product. After centrifugation, the crude 
product was dried in air and purified on a HPLC system with detection wavelength (220 
nm).    
 As shown in Figure 4.4, the synthesis procedure of iRGD is similar as that of 
MA-GG-PLGLAG-iRGD with minor modification.  
 
4.3.4 Preparation and molecular weight (MW) measurement of  
polymer conjugate P-DOX 
 The synthetic scheme of P-DOX is shown in Figure 4.5. Monomer HPMA (416 
mg, 0.97 mmol), monomer MA-GFLG-DOX (89 mg, 0.03 mmol), initiator V-65 (30 mg, 
0.036 mmol), and a mixture of dimethyl sulfoxide (DMSO)/H2O was added to an ampoule.





































































































polymerization was conducted at 51 oC for 10 h. The polymer was precipitated in a 
mixture of diethyl ether and acetone. The crude product was first purified on an LH-20 
column, and further purified on Superose 6 HR10/30 preparative column in an AKTA 
FPLC system (Pharmacia) equipped with refractive index (Optilab rEX) and light 
scattering MiniDawn TREOS detectors (Wyatt Technology Inc, Santa Barbara). Sodium 
acetate (0.1 M) in a mixture of 30% acetonitrile/70% DI water (v/v) (pH = 6.5) was used 
as the eluent, and the flow rate was 1 mL/min.  
 The molecular weight of P-DOX was measured on a Superose 6 HR10/30 
analytical column?and the flow rate was 0.4 mL/min. HPMA homopolymer fractions 
were used as molecular weight standards.  
 
4.3.5 Synthesis and MW measurement of polymer conjugate  
P-DOX-PLGLAG-iRGD 
 As shown in Figure 4.6, the polymer conjugate P-DOX-PLGLAG-iRGD was 
prepared by conventional radical polymerization. Briefly, monomer HPMA (70.6 mg, 
0.493 mmol), monomer MA-GFLG-DOX (15.1 mg, 0.015 mmol), monomer MA-GG-
PLGLAG-iRGD (25 mg, 0.015 mmol) initiator V-65 (5.13 mg, 0.018 mmol), and a 
mixture of DMSO/H2O solvent was added to an ampoule. The ampoule was sealed after 
the mixture was bubbled with nitrogen for 30 min. Then the polymerization was 
conducted at 51 oC for 10 h. The purification and MW measurement methods are the 










Figure 4.6: Synthetic scheme of polymer conjugate P-DOX-PLGLAG-iRGD
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4.3.6 Determination of the DOX content in conjugates P-DOX  
and P-DOX-PLGLAG-iRGD 
 The DOX content in conjugates P-DOX and P-DOX-PLGLAG-iRGD was 
calculated by measuring the DOX UV absorbance in methanol. General procedure for 
testing DOX UV absorbance in a solution of P-DOX-PLGLAG-iRGD in methanol: (i) P-
DOX-PLGLAG-iRGD (2.26 mg) was dissolved in 10 mL methanol; (ii) 1 mL solution  
was transferred to a spectrophotometer cell and UV absorbance was scanned from 200 
nm to 800 nm with Varian UV-Vis spectrophotometers, with blank methanol used as the 
reference; (iii) the UV absorbance at 482 nm was used for DOX concentration calculation. 
 
4.3.7 Determination of the iRGD content in P-DOX-PLGLAG-iRGD 
 The iRGD content in conjugate P-DOX-PLGLAG-iRGD was determined by 
amino acid analysis. The first step was to hydrolyze the peptide by dissolving 2.5 mg of 
conjugate P-DOX-PLGLAG-iRGD in 0.5 mL of 6 M HCl and heating at 110 oC for 24 h. 
The following steps were similar as the procedure for measuring DUPA contents 
(Chapter 2.3.6). Aspartic acid (1 mM, 2.5 mM, 5 mM) and alanine (0.3 mM, 1 mM, 3 
mM) were used for calibration.  
 
4.3.8 Cell culture 
Human prostate cancer DU-145 cells (ATCC, Manassas, VA) were grown in 
RPMI-1640 media (Sigma-Aldrich, St. Louis, MO) containing 10% (v/v) fetal bovine 
serum (FBS), 100 U????????????????????????????????????????????????????????????????????
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37 oC in a humidified atmosphere of 5% CO2 (v/v). Cells were passaged every 2-4 d and 
stopped at passage 20. 
 
4.3.9 In vitro doxorubicin cellular uptake 
DU-145 cells were seeded at a density of 4*105 cells/well in 6-well plates and 
incubated at 37 oC for 24 h to allow cell attachment. After removing the media, the cells 
treated with 9 ?M [iRGD] equivalent of free iRGD, 10 ?M [DOX] equivalent of P-DOX, 
9 ?M [iRGD] equivalent of free iRGD plus 10 ?M [DOX] equivalent P-DOX, or 9 ?M 
[iRGD] and 10 ?M [DOX] equivalents of P-DOX-PLGLAG-iRGD for 24 h. The cells 
were washed and detached from plates with cold PBS. After being centrifuged and 
removed the supernatant, the cells were resuspended in PBS and measured with flow 
cytometry. 
 
4.3.10 Cell cycle arrest 
The DU-145 cells were seeded at a density of 4*105 cells/well in 6-well plates and 
incubated at 37 oC to allow adherence to plates. After 24 h, the media were replaced with 
9 ?M [iRGD] equivalent of free iRGD, 10 ?M [DOX] equivalent of P-DOX, 9 ?M 
[iRGD] equivalent of free iRGD plus 10 ?M [DOX] equivalent P-DOX, or 9 ?M [iRGD] 
and 10 ?M [DOX] equivalents of P-DOX-PLGLAG-iRGD for another 24 h. After 
removing the drug solution, the cells were washed and detached with cold PBS and 
centrifuged. The supernatant was removed and the cells were fixed with 80% ethanol for 
at least 2 h. After being washed with PBS, the fixed cells were re-suspended in 500 µL of 
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propidium iodide (PI) staining solution (50 µg/mL PI, 200 µg/mL RNase) and analyzed 
on a flow cytometer. 
 
4.3.11 Apoptosis 
DU-145 cells were seeded at a density of 4*105 cells/well in 6-well plates and 
incubated at 37 oC for 24 h to allow cell attachment. The media was replaced with 9 ?M 
[iRGD] equivalent of free iRGD, 10 ?M [DOX] equivalent of P-DOX, 9 ?M [iRGD] 
equivalent of free iRGD plus 10 ?M [DOX] equivalent P-DOX, or 9 ?M [iRGD] and 10 
?M [DOX] equivalents of P-DOX-PLGLAG-iRGD for another 24 h. The general 
procedure for preparing samples for measuring apoptosis: (I) the cells were detached 
from 6-well plates, and transferred to 1.5 mL Eppendorf vials; (II) the cells were 
centrifuged to remove the supernatant, and washed with 1X binding buffer; (III) the cells 
were re-suspended in 200 µL of 1X binding buffer; (IV) Annexin V (5 µL) and 
propidium iodide (10 µL) were added to the cell suspension, and the suspension was 
incubated at room temperature for 5-15 min in the dark; (V) the cells were analyzed by 
flow cytometry.  
 
4.3.12 Cell cytotoxicity 
 Cytotoxicity of DOX conjugates and controls against DU-145 cells was assessed 
by CCK-8 assay. DU-145 cells were seeded at a density of 3,500 cells/well in a 96-well 
plate and cultured at 37 oC for 24 h. The media was then replaced with fresh culture 
media containing 9 ?M [iRGD] equivalent of free iRGD, 10 ?M [DOX] equivalent of P-
DOX, or 9 ?M [iRGD] equivalent of free iRGD plus 10 ?M [DOX] equivalent P-DOX, 
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or 9 ?M [iRGD] and 10 ?M [DOX] equivalents of P-DOX-PLGLAG-iRGD and cultured 
for 12 h or 24 h. The drug solutions were replaced with 100 µL of fresh media and 
cultured for another 60 h or 48 h. The media were replaced with 100 µL of fresh media 
and 50 µL of diluted CCK-8 solution. The formazan dye formed was detected at 
absorbance wavelength 450 nm, and 630 nm was used as a background.  
 
4.3.13 Multicellular tumor spheroid formation 
 To a 0.5% agar coated, 10-mm diameter Petri-dish was added 2*106 DU-145 cells 
in 15 mL of RPMI media supplemented with 10% fetal bovine serum (FBS), 50 U/mL 
penicillin, and 50 µg/mL streptomycin. Cells were grown at 37 oC in a humidified 
atmosphere with 5% CO2 (v/v). The size of spheroids was monitored with a EVOS 
fluorescence microscope (AMG).  
 
4.3.14 DOX conjugates accumulation in multicellular tumor spheroids 
 When most of the spheroids grew to 100-???????????????, the spheroids were 
transferred to 15 mL conical base plastic tube and allowed to settle for 2 min. The 
supernatant was removed, and the spheroids were transferred to 24-well plates and 
incubated with 9 ?M [iRGD] and/or 10 ?M [DOX] equivalents of iRGD, P-DOX, a 
mixture of iRGD and P-DOX, or P-DOX-PLGLAG-iRGD for 24 h. After being washed 
with PBS three times, the spheroids were disassociated with accutase (Invitrogen) to 




4.3.15 DOX conjugates penetration in multicellular tumor spheroids 
 The DU-145 prostate cancer spheroids were incubated with 9 ?M [iRGD] 
and/or10 ?M [DOX] equivalents of iRGD, P-DOX, a mixture of iRGD and P-DOX, or P-
DOX-PLGLAG-iRGD for 24 h. After being washed and fixed, the DOX fluorescence in 
spheroids was measured with Olympus FV1000 confocal microscope. The images were 
analyzed using ImageJ software.  
 
4.3.16 Statistical analysis 
 Average results are expressed as mean ± SEM or mean ± SD. The statistical 
difference between groups was assessed by a one-way analysis of variance (ANOVA) 
plus post-hoc tests ?????? ????????? ?????? ?????????? ?? ??????? ?? ????? ????? ???????????
statistically significant. 
 
4.4 Results and Discussion 
4.4.1 Design, synthesis, and characterization of monomer MA-GFLG-DOX 
 The conventional method to prepare monomer MA-GFLG-DOX from MA-
GFLG-OH included two steps: the first step is to prepare MA-GFLG-4-nitrophenyl ester 
(MA-GFLG-ONp) by the reaction of MA-GFLG-OH and 4-nitrophenol in the presence 
of N,N?-dicyclohexylcarbodiimide (DCC) in DMF; the second step is to react MA-
GFLG-ONp with DOX to produce MA-GFLG-DOX (32). This procedure is laborious to 
remove the dicyclohexyl urea (DCU) side product from the coupling agent DCC. As 
shown in Figure 4.2, we prepared monomer MA-GFLG-DOX by direct reaction of MA-
GFLG-OH with DOX using the coupling agent HATU at low temperature. The coupling 
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reaction was preferentially induced at the primary amine in DOX by controlling the 
reaction temperature.  
 
4.4.2 Design, synthesis, and characterization of monomer  
MA-GG-PLGLAG-iRGD and free iRGD 
 To incorporate iRGD into the drug carrier system via a MMP-2 degradable spacer 
-PLGLAG-, two general methods are potentially able to achieve this aim. The first 
method is to prepare the drug carrier precursor first, then conjugate the iRGD to the drug 
carrier precursors. The second method is to prepare the monomer form of iRGD first, 
then incorporate the iRGD into the polymer carrier by direct copolymerization. Because 
of the presence of disulfide bond, primary amine, and carboxyl group in iRGD, we prefer 
to use the second method to directly incorporate iRGD into drug carrier system to avoid 
undesired side reactions. Because iRGD strictly requires the exposure of C terminus to 
keep its activity, we prepared the monomer by conjugation starting from the N-terminus 
of iRGD (34). As shown in Figure 4.3, we designed a concise method to prepare the 
monomer form of iRGD (MA-GG-PLGLAG-iRGD) with solid phase synthesis. This 
procedure is easy to handle because all of the conjugation and cyclization reactions 
occurred in solid phase when attached to resin. In particular, the cyclization reaction on 
resin is able to avoid the formation of intermolecular disulfide bond between two iRGDs. 
The  structures  of  free  iRGD  and  monomer  MA-­GG-­PLGLAG-­iRGD  were  confirmed  by  
MALDI-­TOF   (matrix-­assisted   laser   desorption   ionization,   time-­of-­flight)   mass  



















the   monomer   MA-­GG-­PLGLAG-­iRGD.   The   peak   at   m/z   948.37   in   Figure   4.8  
corresponds  to  [M+H]+  of  the  free  iRGD.  
 
4.4.3 Synthesis and characterization of polymer conjugates  
P-DOX and P-DOX-PLGLAG-iRGD 
 The conjugates P-DOX (Figure 4.5) and P-DOX-PLGLAG-iRGD (Figure 4.6) 
were prepared by conventional radical polymerization. The monomers MA-GFLG-DOX 
and MA-GG-PLGLAG-iRGD are soluble in DMSO, but the polymerization rate in 
DMSO is slow. To balance the solubility of monomers and reaction rate, we chose a 
mixture of DMSO and DI water (DMSO/water =2/1) as the solvent to prepare the two 
DOX conjugates with conventional polymerization. By using conventional 
polymerization, both P-DOX and P-DOX-PLGLAG-iRGD can be prepared in 10 h.  
 The molecular weight, molecular weight distribution, DOX, and iRGD content in 
conjugates P-DOX and P-DOX-PLGLAG-iRGD are summarized in Table 4.1. The 
average number of iRGD units in one polymer chain is 4.6.  
 
4.4.4 Cellular uptake 
  We used flow cytometry to quantitatively measure DOX uptake in monolayer 
DU-145 prostate cancer cells after incubation with P-DOX-PLGLAG-iRGD and controls 
for 24 h (Figure 4.9). Higher fluorescence intensity was detected in P-DOX and P-DOX 
plus iRGD treated groups compared to control and iRGD treated group. P-DOX-
PLGLAG-iRGD treated group shows the largest rightward shift in the histogram, 









































DOX Conjugate Mn (kDa) Mw (kDa) Mw/Mn DOX (wt%) iRGD (wt%)
P-DOX 69.8 120.0 1.72 8.35 N/A









Figure 4.9: Uptake of DOX conjugates and controls in DU-145 cell monolayers by 
measuring the DOX fluorescence. 
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PLGLAG-iRGD treated group. In contrast, the mixture of iRGD with P-DOX only 
resulted in a slight increase of uptake and accumulation of P-DOX in DU-145 cells in the 
tested concentration and incubation time.  
 
4.4.5 Cell cycle arrest assay 
 It was reported that the treatment of prostate cancer DU-145 cells with DOX 
resulted in G2/M arrest (35). We performed cell cycle arrest assay to check whether the 
enhanced accumulation of DOX in the P-DOX-PLGLAG-iRGD treated group could lead 
to increased G2/M cell cycle arrest. Consistent with DOX uptake results, the highest 
percentage ((41.6 ± 7.2)%) of cells in G2/M phase was found in the P-DOX-PLGLAG-
iRGD treated group (Figure 4.10). While P-DOX and a mixture of iRGD and P-DOX 
only induced a mild increase of G2/M arrest ((31.7 ± 7.1)%, (32.9 ± 6.4)%, respectively). 
These results further demonstrated that the conjugated form of iRGD can enhance the 
accumulation of DOX conjugates in DU-145 prostate cancer cells. 
 
4.4.6 Apoptosis 
 The concentrations of DOX and iRGD used in this study were equivalent to those 
used in the uptake and cell cycle assays to assess whether the uptake and cell cycle arrest 
were associated with the cell apoptosis. The percentages of late apoptotic, early apoptotic, 
and live cells were analyzed on flow cytometer after double staining the cells with FITC-
Annexin V and PI (Figure 4.11). Annexin V+/PI+ cells were considered as late apoptotic 






Figure 4.10: DU-145 cell cycle distribution after treatment with DOX conjugates and 
related controls. (A) Representative profiles. (B) Percentage of cells in G1 phase. (C) 
Percentage of cells in G2/M phase. (D) Average percentages of cell cycle distribution. 
Average data were presented as mean ± SD. Statistics:  One  Way  ANOVA  plus  ?????????  















Figure 4.11: Induced apoptosis in DU-145 cells after treatment with DOX conjugates and 
related controls. 
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apoptotic cells, shown in the lower right quadrant. Annexin V-/PI- cells shown in the 
lower left quadrant were considered as live cells. The percentages of early apoptotic DU-
145 cells were counted as 1.0%, 1.2%, 7.9%, 6.9%, and 33.6% for control, iRGD, P-
DOX, P-DOX plus iRGD, and P-DOX-PLGLAG-iRGD treated groups, respectively. The 
percentages of late apoptotic DU-145 cells were counted as 14.4%, 23.6%, 22.9%, 27.1%, 
and 33.7%, respectively. Compared to control and iRGD group, both P-DOX and the 
mixture of P-DOX and iRGD enhanced early apoptosis. P-DOX-PLGLAG-iRGD treated 
group showed the highest early and late apoptosis compared to control and other treated 
groups.  
 
4.4.7 In vitro cellular cytotoxicity assays 
 We evaluated the cytotoxicity of DOX conjugates and related controls against 
DU145 prostate cancer cells by determining the viable cells with CCK-8 assay. The cells 
were incubated with 10 µM [DOX] equivalent and/or 9 ?M [iRGD] equivalent of P-
DOX-PLGLAG-iRGD, a mixture of P-DOX and iRGD, P-DOX, and iRGD for 12 h or 
24 h. As shown in Figure 4.12, the conjugate P-DOX-PLGLAG-iRGD is more toxic to 
DU-145 prostate cancer cells than P-DOX or the mixture of P-DOX and iRGD. The 
highest cytotoxicity of P-DOX-PLGLAG-iRGD could be, at least in part, attributed to its 
fast intracellular uptake. The fact that the conjugate of P-DOX-PLGLAG-iRGD is more 
toxic than that of the mixture of P-DOX and iRGD further supports the conclusion that 
the targeting interaction between RGD and integrin on DU-145 cell surface possibly 










Figure 4.12: In vitro cytotoxicity of P-DOX-PLGLAG-iRGD and related controls against 
DU-145 prostate cancer cells. (A) 12 h. (B) 24 h. Statistics:   One  Way   ANOVA   plus  
????????? ????-­hoc   test   (P<0.001   =   ***,   0.001<P<0.01   =   **,   0.01<P<0.05   =   *,   not  









4.4.8 Accumulation of DOX conjugates and related controls  
in multicellular tumor spheres (MTS) 
 MTS are more considered as one of the primary tools for drug development (36). 
Compared to 2D monolayer tumor cells, 3D MTS closely resemble 3D tumor tissues and 
mimic the tumor microenvironment (37). MTS is an excellent model for drug delivery 
studies because it mimics the physiological barriers in solid tumors (38). The VEGF 
production, Ki-67, and gene expression profile in 3D prostate cancer spheres is similar to 
the solid tumors in immune-derived mice (39). To bridge the gap between cell culture 
and live tissue, DU-145 MTS were used to investigate the accumulation and penetration 
of DOX conjugates.  
 We evaluated DOX conjugates accumulation in DU-145 MTS by analyzing the 
DOX fluorescence in disassociated cells using flow cytometry. As shown in Figure 4.13, 
the cells in the P-DOX-PLGLAG-iRGD treated group have the strongest fluorescence 
intensity. Consistent with monolayer cell uptake results, the cells from spheroids 
following treatment with a mixture of P-DOX and iRGD, or P-DOX also have enhanced 
fluorescence intensity compared to control groups. 
 
4.4.9 MTS penetration of DOX conjugates 
 We evaluated DOX conjugates penetration in DU-145 MTS using confocal 
microscopy (Figure 4.14). To keep the morphology of tested spheroids intact, we fixed 
the spheroids with formalin. The presence of DOX within spheroids was visualized by 
??????????????s intrinsic fluorescence. The images were converted to surface plot by 







   
 
Figure 4.13: Accumulation of DOX conjugates in DU-145 multilayer  

















Figure 4.14: Penetration of DOX conjugates or controls in DU-145 MTS (surface plots of 







fluorescence intensity in P-DOX-PLGLAG-iRGD treated spheroids over P-DOX treated 
spheroids was observed. 
 
4.5 Conclusion 
In this study, a stimuli responsive drug delivery system with iRGD conjugated to 
drug carrier via a MMP-2 cleavable spacer was successively developed for prostate 
cancer treatment. Both confocal fluorescene microscopy and flow cytometry studies 
demonstrated that the conjugated form of iRGD enhanced the DOX uptake in prostate 
cancer DU-145 monolayer and multilayer cells. We evaluated the in vitro activity of 
DOX conjugates on DU-145 cell cycle arrest, cell apoptosis, and cell death. The 
penetration of DOX conjugates was tested in vitro tumor spheroids. The results 
demonstrated that the conjugate P-DOX-PLGAGL-iRGD has better penetration ability 
than P-DOX and a mixture of P-DOX and iRGD. This strategy by conjugating iRGD to 
drug carrier via a -PLGLAG- spacer enhances the penetration and accumulation of DOX 
in tumor. Consequently, a lower dosage of DOX in this new formulation has the potential 
to achieve the same efficacy as reported dosage. This strategy can broaden the application 
of DOX for cancer treatment through bypassing the dose-limiting cardiotoxicity (40,41). 
Consistent with the results from other research group, we further demonstrated that tumor 
spheroids are excellent model for testing drug penetration before moving for in vivo 
evaluation (42). Together our data demonstrated the advantages of our novel drug 
delivery system with MMP-2 controlled release of iRGD. This strategy opens up avenues 
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HPMA COPOLYMER CXCR-4 ANTAGONIST BKT140 CONJUGATES FOR 
INHIBITING PROSTATE CANCER CELL MIGRATION 
 
5.1 Summary 
 In this chapter, we describe the design, synthesis, structure validation, and 
biological properties of a N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer 
CXCR-4 antagonist (BKT140) conjugate.  BKT140 was attached to HPMA backbone via 
a matrix metallopeptidase 2 (MMP-2) cleavable spacer (-PLGLAG-). Both free BKT140 
and monomer MA-GG-PLGLAG-BKT140 were prepared by solid phase synthesis. 
HPMA copolymer-BKT140 conjugate (P-PLGLAG-BKT140) was prepared via 
Reversible Addition-Fragmentation Chain Transfer (RAFT) copolymerization of HPMA 
and MA-GG-PLGLAG-BKT140. The -PLGLAG- spacer was cleaved in prostate cancer 
cells growth media at a minimum of two sites. The in vitro cell cytotoxicity results show 
that the free BKT140 and P-PLGLAG-BKT140 have the same activities against PC-3 
cells, indicating the conjugation of BKT140 to HPMA did not impact the functionality of 
BKT140. The migration results shown that both HPMA copolymer BKT140 conjugate 
and free BKT140 inhibited the CXCL12 induced PC-3 prostate cancer cell migration. 





 Metastasis accounts for 90% of cancer-associated mortality, and the 5-year 
survival of metastatic prostate cancer is only about 30% (1,2). Prostate cancer can 
metastasize to lymph nodes, liver, and thorax, but the most common metastatic site is 
bone (84% of 74,826 patients) (3,4). More and more evidence has demonstrated prostate 
cancer cells use CXCR4/CXCL12 pathway to migrate from primary tumor to bone (5,6). 
CXCR4 was detected in most (94.2%) of metastatic prostate cancer. In addition, CXCR4 
and CXCL12 were significantly elevated in localized and metastatic prostate cancer in 
samples of over 600 patients (7,8). The overexpression of CXCR4 accelerates prostate 
cancer metastasis by promoting the migration and invasion ability of prostate cancer cells 
toward CXCL12 (9,10). Blocking or inhibiting the CXCL12/CXCR4 interaction by anti-
CXCR4 antibody or CXCR4 antagonists impairs the migration and invasion potential of 
prostate cancer cells (9,11,12). 
 In this study, we aim to develop a N-(2-hydroxypropyl)methacrylamide (HPMA) 
copolymer CXCR-4 antagonist conjugate to block the migration of prostate cancer cells. 
4F-benzoyl-TN14003 (BKT140) was chosen as the CXCR4 antagonist to develop new 
therapeutics based on two major reasons: (i) BKT140 has a high binding affinity (1 nM) 
toward CXCR4 (13), and (ii) BKT140 is safe in vivo (14). However, two factors hinder 
the in vivo application of BKT140. First, BKT140 is sensitive to enzymatic degradation 
in the circulation because it is a peptide. Second, the renal clearance of BKT140 is fast 
because the mass of BKT140 is less than 5 kDa (15).  The most common strategy to 
prolong the plasma residence time of peptide is to conjugate the peptide to a water-
soluble polymer (15).  
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 BKT140 was conjugated to HPMA copolymer via a MMP-2 cleavable spacer (-
PLGLAG-) (16,17). MMP-2 was selected as the cleavage enzyme because MMP-2 is 
highly expressed in prostate cancer cells (9,18,19). We hypothesized that the conjugation 
of BKT140 to HPMA copolymer will prolong the plasma residence time of BKT140 
during circulation. Once HPMA copolymer-BKT140 conjugates reach the tumor area, the 
BKT140 will be released from the conjugate after the spacer (-PLGLAG-) is cleaved by 
MMP-2.  
 
5.3 Material and Methods 
5.3.1 Materials 
 Recombinant human CXCL12 was purchased from PeproTech (Rocky Hill, NJ). 
1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluoro 
-phosphate (HATU), protected amino acids, and Rink amide MBHA resin were 
purchased from AAPPTEC (Louisville, KY). 4,4?-Azobis(4-cyanopentanoic acid) (V-
501) was purchased from Wako (Japan). Tris(2-carboxyethyl) phosphine hydrochloride 
(TCEP) was purchased from Thermo Scientific (Waltham, MA). General solvents were 
purchased from Fisher Scientific (Fair Lawn, NJ). Trifluoroacetic acid (TFA) was 
purchased from Acros (Fair Lawn, NJ). HPMA (20), MA-GG-OH (21), and 4-
cyanopentanoic acid dithiobenzoate (CPAD) (22) were prepared as described in literature. 
All other chemicals were purchased from Sigma Aldrich (St. Louis, MO) unless 





5.3.2 Synthesis of free CXCR4 antagonist BKT140 
The resin bound linear peptide BKT140 was prepared by solid phase synthesis 
using a PS-3 peptide synthesizer (Protein Technologies, Inc). As shown in Figure 5.1, the 
synthesis started from the deprotection of Fmoc group on Resin by mixing the Rink 
amide MBHA resin (300 mg, 0.52 mmol/g, 156 µmol) with 20% piperidine in DMF. 
Then the protected amino acids (Fmoc-Arg(Pbf)-OH, Fmoc-Cys(Acm)-OH, Fmoc-Cit-
OH, Fmoc-Arg(Pbf)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Pro-OH, Fmoc-D-Lys(Boc)-OH, 
Fmoc-Lys(Boc)-OH, Fmoc-Cit-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Cys(Acm)-OH, Fmoc-
Nal-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Arg(Pbf)-OH), and 4-fluorobenzoic acid were 
sequentially attached to the resin in the presence of HATU (169 mg, 444.6 µmol).   
 The MBHA resin bound linear peptides were suspended in a solution of 
Tl(OOCF3)3 (254mg, 468 µmol) in DMF and shaken for 2h. After the Tl(OOCF3)3 
solution was removed by filtration, the remaining resin was washed with DMF and 
methanol respectively for three times, and then dried. 
 A mixture solution (TFA/TIPS/H2O = 95/2.5/2.5) (10 mL) was added to the dried 
resin and shaken at room temperature for 3 h. Then the solution was filtered, and  
concentrated under vacuum. The remaining solution was added slowly into cold diethyl 
ether. The suspension obtained was centrifuged at 4000 RPM, and the crude solid 








5.3.3 Reduction of free CXCR4 antagonist BKT140 
 The scheme for reduction of BKT140 is shown in Figure 5.2. BKT 140 (0.2 mg) 
was added to 0.5 mL of 10 mM tris(2-carboxyethyl) phosphine hydrochloride (TCEP) in 
phosphate buffered saline (PBS) (10 mM) with 1 mM ethylene diamine tetra acetic acid 
(EDTA), and incubated at 37 oC for 2 h. 
 
5.3.4 Synthesis of monomer MA-GG-PLGLAG-BKT140 
 The synthetic scheme of monomer MA-GG-PLGLAG-BKT140 is shown in 
Figure 5.3. The first step was to prepare the Rink amide MBHA bound protected linear 
BKT140 peptide. This procedure was similar as the procedure in the synthesis of free 
BKT140; the only difference was that Fmoc-D-Lys(Dde)-OH was used instead of Fmoc-
D-Lys(Boc)-OH.  
The second step was to selectively remove the 1-(4,4-dimethyl-2,6-
dioxocyclohex-1-ylidene)-3-ethyl (Dde) protecting group  from the D-Lys8 amino acid 
residue by mixing the Rink amide MBHA bound protected linear BKT140 peptide with 2% 
hydrazine in DMF for 10 min.  
The next step was to sequentially attach protected amino acids (Fmoc-Gly-OH, 
Fmoc-Ala-OH, Fmoc-Leu-OH, Fmoc-Gly-OH, Fmoc-Leu-OH, Fmoc-Pro-OH) and MA-
GG-OH to resin.   
The following step was to cyclize the linear peptide by mixing the resin bound 
linear BKT 140 peptide with a solution of Tl(OOCF3)3 (254 mg, 468µmol) in DMF for 




















The final step was to cleave the peptide from the resin with a mixture of TFA (9.5 
mL), TIS (0.25 mL), and H2O (0.25 mL) for 3 h. The acid liable protecting groups were 
also removed in this step. After concentrating under vacuum, the remaining residue was 
added into cold diethyl ether to precipitate the crude product. The crude MA-GG-
PLGLAG-BKT140 was obtained after removing the supernatant.  
 
5.3.5 Purification and characterization of BKT140 and monomer  
MA-GG-PLGLAG-BKT140 
 The free BKT140 and monomer MA-GG-PLGLAG-BKT140 were purified by 
RP-HPLC (Agilent 1100 series) equipped with a semipreparative ZORBAX 300SB-C18 
column (5 µm, 9.4*250 mm) from Agilent Technologies (Santa Clara, CA). Buffer A 
(0.1% TFA in DI water) and Buffer B (0.1% TFA in acetonitrile) were used as the elution 
agents. The structure of BKT140 and MA-GG-PLGLAG-BKT140 were analyzed by 
matrix-assisted laser desorption/ionization time of flight (MALDI-TOF) mass 
spectrometry (Voyager-DE STR Biospectromety Workstation, Perseptive Biosystems, 
Framingham, MA).  
 
5.3.6 Preparation of HPMA copolymer-BKT140 conjugate 
 As shown in Figure 5.4, the HPMA copolymer-BKT140 conjugate P-PLGLAG-
BKT140 was prepared via RAFT polymerization. Briefly, monomer HPMA (86 mg), 
monomer MA-GG-PLGLAG-BKT140 (35 mg), chain transfer agent 4-cyanopentanoic 
acid dithiobenzoate (CPAD) (0.172 mg), initiator V501 (0.172 mg), and a mixture of 



















for 30 min, the ampoule was sealed and the mixture was incubated at 69 oC for 48 h. The 
reaction mixture was cooled to room temperature and added into a mixture of acetone and 
diethyl ether. The precipitate was collected after removing the supernatants by 
centrifugation.  
 
5.3.7 Purification and characterization of P-PLGLAG-BKT140 
 The polymer conjugate P-PLGLAG-BKT140 was purified by size exclusion 
chromatography using a Superose 6 HR10/30 preparative column on an AKTA FPLC 
system (Pharmacia) equipped with refractive index (RI) and UltraViolet (UV) detectors. 
The buffer with 0.1 M of sodium acetate in a mixture of 30% acetonitrile in DI water 
(v/v) (pH = 6.5) was used as the eluant, and the flow rate was 1 mL/min.  
 The number average molecular weight (Mn), weight average molecular weight 
(Mw) and polydispersity (Mw/Mn) of P-PLGLAG-BKT140 were measured on a Superose 
6 HR10/30 analytical column using the same instrument and buffers as for purification. 
The flow rate was 0.4 mL/min. HPMA homopolymer fractions were used for molecular 
weight calibration.  
The BKT140 content in P-PLGLAG-BKT140 was determined by amino acid 
analysis. The general procedure was similar as the procedure for measuring DUPA 
content in DUPA targeted HPMA copolymer-DTX conjugates (Chapter 2.3.6). Tyrosine 






5.3.8 Cell culture 
PC-3 prostate cancer cells (ATCC) were grown in RPMI-1640 media 
supplemented with 10% fetal bovine serum (FBS), 100 U??????????????????????????????
streptomycin (Gibco, Carlsbad, CA) at 37 oC in a humidified atmosphere of 5% CO2 
(v/v). Cells were passaged every 3-4 d and stopped at passage 20. 
 
5.3.9 In vitro cleavage study 
 When PC-3 prostate cancer cells grew to 90% confluence, the cell culture media 
was collected. To PC-3 cell culture media (10 mL) was added 0.05 mL of monomer MA-
GG-PLGLAG-BKT140 in tris(hydroxymethyl)aminomethane (Tris) solution (1 mg/mL) 
and kept at 37 oC for 2 h. Acetonitrile (10 mL) was added to the above mixture and 
centrifuged to remove the precipitate. The collected solution was concentrated until dry, 
and the residue was redissolved in 1.5 mL of acetonitrile and DI water mixture (v/v = 
1/1). After filtration, the mixture was checked with MALDI-TOF mass spectrometry.  
 
5.3.10 Cell cytotoxicity assay 
 PC-3 cells were seeded at a density of 3,500 cells/well in a 96-well plate for 24 h. 
Then the media was replaced with various concentrations (25 µM, 10 µM, 5 µM, 5 µM, 
0.05 µM) of free BKT140 and of BKT140 equivalent of P-BKT140 in RPMI-160 media 
with supplements. After being incubated at 37 oC for 72 h, the drug solutions were 
aspirated and replaced with 100 µL fresh culture media and 50 µL of diluted CCK-8 
solution. Then the UV absorbance of the mixture was measured at 450 nm, with a 
reference of 630 nm.  
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5.3.11 In vitro cell migration assay 
 To the bottom chamber of 6.5 mm transwell (Corning, Corning, NY) with 8 µm 
pore polycarbonate membrane was added 0.65 mL of RPMI-1640 serum free media with 
or without 400 ng CXCL12/mL. To the top chamber of transwell was added PC-3 cells 
(1*105 cells in 0.1 mL) and incubated at 37 oC in a humidified atmosphere of 5% CO2 
(v/v). After 24 h, the nonmigratory cells on upper membrane surface were removed. The 
cells on bottom surface were stained with DAPI. The cells that migrated through to the 
lower membrane surface were stained with 4???-diamidino-2-phenylindole (DAPI, 1 
µg/mL, Sigma). Migrating cells were quantified by manually counting 15 representative 
fields, using an AMG inverted microscope. 
 
5.3.12 Statistical analysis 
 Data are expressed as mean ± SEM or mean ± SD. Statistical comparisons of 
means between groups were performed by a one-way analysis of variance (ANOVA) plus 
post-hoc tests ?????? ????????? ?????? ?????????? ?? ??????? ?? ????? ????? ???????????
statistically significant. 
 
5.4 Results and Discussion 
5.4.1 Design, synthesis, and characterization of BKT140  
and monomer MA-GG-PLGLAG-BKT140  
 All the conjugation reactions were conducted on solid phase support. The D-Lys 
at position 8 was chosen for conjugation because the conjugation at this position does not 
interfere with the binding affinity of BKT140 toward CXCR4 [28?30]. To make sure that 
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the reaction could be selective at D-Lys8 and rather than L-Lys7, we selected Fmoc-D-
Lys(Dde)-OH and Fmoc-L-Lys(Boc)-OH for preparing the monomer MA-GG-PLGLAG-
BKT140. The Dde protecting group can be selectively removed with 2% hydrazine, while 
other protecting groups (tBu, Boc, Pbf, Acm) are stable at this condition. The structure of 
monomer MA-GG-PLGLAG-BKT140 was validated by MALDI-TOF mass 
spectrometry. The calculated mass of monomer MA-GG-PLGLAG-BKT140 [M+H]+ is 
2849.45, and the found mass is 2849.30 (Figure 5.5).  
 For preparing free BKT140, Fmoc-D-Lys(Boc)-OH was used because it is 
cheaper than Fmoc-D-Lys(Dde)-OH. The BKT140 structure was confirmed by measuring 
the mass of BKT140 and its reduced product. As shown in Figure 5.2, the reduction of 
the disulfide bond in BKT140 produced two sulfhydryl groups in linear BKT140. The 
mass of the linear BKT140 is 2 Da higher than that of original BKT140. The peak at 
2159.17 corresponds to the mass of the BKT140 ([M+H]+) (Figure 5.6). The peak at 
2161.14 corresponds to the mass of the reduced product from BKT140 ([M1+H]+) (Figure 
5.7). 
 
5.4.2 Preparation and characterization of P-PLGLAG-BKT140 
 The obvious advantages of ?Green? RAFT polymerization are controlling polymer 
structures and functionality (26). The homopolymer HPMA can be prepared in aqueous 
media (27). The P-PLGLAG-BKT140 was prepared by RAFT polymerization of 
monomers HPMA and MA-GG-PLGLAG-BKT140. 4-cyano-pentanoic acid 















































Figure 5.7: Mass spectrum of reduced product from free BKT140. 
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chain transfer agent (CTA) and initiator, respectively. A small amount of DMSO was 
added to enhance the solubility of monomer MA-GG-PLGLAG-BKT140 and initiator V-
501 in the reaction mixture.  
 The molecular weight and molecular weight distribution of P-PLGLAG-BKT140 
were analyzed by size exclusion chromatography. The number average, weight average 
molecular weights, and polydispersity (Mw/Mn) of P-PLGLAG-BKT140 were 1.00 * 105 
Da, 1.23 * 105 Da, and 1.23, respectively.  
 The content of BKT140 in the polymer conjugate P-PLGLAG-BKT140 was 
measured by amino acid analysis. The measured content was 68.6 nmol BKT140/mg 
polymer, and the weight percent was 14.8% (BKT140/polymer). Alanine and tyrosine 
were used for calibration.  
 
5.4.3 In vitro cleavage results     
 It has previously been demonstrated that peptide -PLGLAG- can be cleaved by 
MMP-2 (16,17,28). In order to check whether BKT140 could be released from the carrier 
in tumor microenvironment, we incubated MA-GG-PLGLAG-BKT140 with PC-3 
prostate cancer cell growth media because the active MMP-2 concentration in PC-3 cell 
growth media is up to 2000 pg/mL (9). The mass spectrum of the mixture was checked 
with MALDI-TOF mass spectrometry, and the result is shown in Figure 5.8. The peaks at 
2849.46 and 2871.36 correspond to the mass of monomer MA-GG-PLGLAG-BKT140 
([M+H]+, [M+Na]+). From the results in Figure 5.8, at least two cleavage sites were 
found in MA-GG-PLGLAG-BKT140. Two cleavage sites are proposed in Figures 5.9 












Figure 5.8: Mass spectrum of cleavage product from monomer MA-GG-PLGLAG-

















Figure 5.9: Proposed cleavage site 1 of monomer MA-GG-PLGLAG-BKT140 after  















Figure 5.10: Proposed cleavage site 2 of monomer MA-GG-PLGLAG-BKT140 after  




proline and leucine residues. The peaks at 2570.31, 2592.29, 2608.29 in Figure 5.8 
correspond to the mass of one cleaved product in Figure 5.9 ([M1+H]+, [M1+Na]+, 
[M1+K]+. In Figure 5.10, it is shown that MA-GG-PLGLAG-BKT140 was also cleaved 
between leucine and glycine residues. The peaks at 2457.26, 2480.20 in Figure 5.8 
correspond to the mass of one cleaved product in Figure 5.10 ([M2+H]+, [M2+Na+H]+. 
 
5.4.4 In vitro cytotoxicity results 
 In order to rule out that the inhibition of cell motility is due to nonspecific 
cytotoxic effects, we conducted an in vitro cytotoxicity assay to find the appropriate 
concentrations of BKT140 for migration and invasion study. Five different 
concentrations (25 µM, 10 µM, 5 µM, 0.5 µM, 0.05 µM) of BKT140 or BKT140 
equivalent of P-PLGLAG-BKT140 were tested against PC-3 prostate cancer cells, and 
the cell cytotoxicity results are summarized in Figure 5.11. P-PLGLAG-BKT140 has 
similar cytotoxicity of as free BKT140, and both BKT140 and P-PLGLAG-BKT140 have 
only minor cytotoxicity against PC-3 prostate cancer cells when the concentration is less 
than 10 µM. Thus, concentrations lower than10 µM will be used for migration studies.  
 
5.4.5 In vitro migration results 
 Based on the above cytotoxicity results, we used 5 µM of BKT140 or BKT140 
equivalent of P-PLGLAG-BKT140 for migration study. As shown in Figure 5.12, 
CXCL12 enhanced the migration of PC-3 prostate cancer cells. Both BKT140 and P-
PLGLAG-BKT140 inhibited the CXCL12 induced migration of PC-3 prostate cancer 









Figure 5.11: In vitro cytotoxicity of BKT140 and P-PLGLAG-BKT140  
















Figure 5.12: Effects of BKT140 and P-PLGLAG-BKT140 on CXCL12 induced 








 We have successfully prepared a prostate cancer tumor microenvironment 
responsive N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer CXCR-4 antagonist 
conjugate (P-PLGLAG-BKT140) via RAFT copolymerization of monomer HPMA and 
MA-GG-PLGLAG-BKT140. We designed a concise scheme to prepare the monomer 
MA-GG-PLGLAG-BKT140. All the conjugation reactions of MA-GG-PLGLAG-
BKT140 were conducted on MBHA resin for easy handling. Fmoc-D-Lys(Dde)-OH and 
Fmoc-L-Lys(Boc)-OH were chosen for the synthesis of the monomer MA-GG-
PLGLAG-BKT140 in order to make sure the reaction selectively occurred at D-Lys8 
rather than L-Lys7. The structures of free BKT140 and monomer MA-GG-PLGLAG-
BKT140 were confirmed by mass spectrometry. The synthesis methodology for P-
PLGLAG-BKT140 can be used to design other formulation of BKT140 conjugates.  The 
spacer (-PLGLAG-) was cleaved by prostate cancer growth media at a minimum of two 
sites. Both free BKT140 and P-PLGLAG-BKT140 have shown the same cytotoxicity 
against PC-3 cells, indicating that the conjugation of BKT140 to HPMA copolymer 
retains the functionality of free BKT140. The migration results shown that both HPMA 
copolymer BKT140 conjugate and free BKT140 inhibited the CXCL12 induced PC-3 
prostate cancer cell migration. The conjugate P-PLGLAG-BKT140 has great impact than 
that of free BKT140. The activities of BKT140 and P-PLGLAG-BKT140 for blocking 
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CHAPTER 6  
 
RESULTS, CONCLUSIONS, AND FUTURE PROSPECTS
 
 Stimuli-responsive targeted drug release systems are important for improving the 
efficacy and reducing the side effect of drugs. Prostate   cancer   is   the   most   frequently  
diagnosed  cancer   in  men  and  has   the  second  highest  mortality   rate   in  United  States.   In  
this   thesis,  we  developed  stimuli-­responsive  targeted  therapeutics   for   inhibiting  primary  
and  metastatic  prostate  cancer  growth.   
 In Chapter 2, we describe the design, synthesis, structure validation, and 
biological properties of targeted and nontargeted N-(2-hydroxypropyl)methacrylamide 
(HPMA) copolymer docetaxel (DTX) conjugates. Docetaxel was conjugated to HPMA 
copolymer via a tetrapeptide spacer (-GFLG-). 3-(1,3-dicarboxypropyl)-
ureido]pentanedioic acid (DUPA) was used as the targeting moiety to actively deliver 
DTX for treatment of  Prostate-Specific Membrane Antigen (PSMA) expressing prostate 
cancer. Short and long spacer DUPA monomers were prepared, and four HPMA 
copolymer-DTX conjugates (nontargeted, two targeted with different molecular weight 
with short spacer, and targeted with long spacer) were prepared via Reversible Addition-
Fragmentation Chain Transfer (RAFT) copolymerization. Following confirmation of 
PSMA expression on C4-??????????????????????????????????????????????????????????????????
against C4-2 tumor cells and their anticancer efficacies were assessed in nude mice 
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bearing s.c. human prostate adenocarcinoma C4-2 xenografts. The in vivo results showed 
that the spacer length between targeting moieties and HPMA copolymer backbone could 
significantly affect the treatment efficacy of DTX conjugates against C4-2 tumor bearing 
nu/nu mice. Moreover, histological analysis indicated that the DUPA targeted DTX 
conjugate with longer spacer had no toxicity in major organs of treated mice. 
 In order to further confirm the importance of spacer length between targeting 
moiety DUPA and HPMA backbone, binding affinity of DUPA targeted conjugates with 
different spacer length against PSMA (+) prostate cancer cells should be tested and 
compared. We hypothesize that the similar in vitro toxicities of the DUPA targeted and 
nontargeted conjugates are the result of free DTX being released from the drug conjugate 
in cell culture conditions and subsequently dominating the toxicological profile. To test 
this hypothesis, other HPMA-drug conjugates with acid-liable (and basic stable) bonds 
should be prepared and tested. To maximize the targeting effect of DUPA, the impact of 
DUPA distribution and number conjugated to HPMA copolymer chain on targeting effect 
should be further investigated.  
 In Chapter 3, a   conjugate   of   the   tumor   homing   peptide   iRGD   and   histone  
deacetylase  inhibitor  valproic  acid  (VPA-­GFLG-­iRGD)  was  developed  and  its  activities  
were   evaluated   in   DU-­145   prostate   cancer   cells.   Conjugates   VPA-­GFLG-­iRGD   and  
GFLG-­iRGD   were   prepared   by   solid   phase   synthesis.   The   activities   of   VPA-­GFLG-­
iRGD  and  related  controls  against  DU-­145  prostate  cancer  cells  were  tested  by  both  cell  
cytotoxicity  and  cell  cycle  arrest  assays.  The  conjugate  VPA-­GFLG-­iRGD  and  a  mixture  
of   VPA   and   GFLG-­iRGD   have   shown   similar   cytotoxicity   against   DU-­145   prostate  
cancer  cells.  However,  the  treatment  of  DU-­145  cells  with  conjugate  VPA-­GFLG-­iRGD  
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resulted   in   a  decreased   percentage  of   cells   in   the  G2  phase,  whereas   the   exposure  of   a  
mixture  of  VPA  and  GFLG-­iRGD  led  to  an  increased  percentage  of  cells  in  the  G2  phase.  
We  also  found  that  GFLG-­iRGD  possessed  cytotoxicity  at  the  tested  concentrations.  
   More   experiments   are   needed   to   investigate   the   uptake   mechanism   of   VPA-­
GFLG-­iRGD  conjugate  into  DU-­145  prostate  cancer  cells.  In  the  present  work,  VPA  was  
conjugated  to  iRGD  via  a  lysosomally  cleavable  spacer  based  on  the  hypothesis  that  this  
conjugate  enters  cells  via  endocytosis.  Other  drug-­iRGD  conjugates,  which  are  formed  by  
linking  drug  with  iRGD  via  a  disulfide  spacer  should  be  investigated  and  compared  with  
the   conjugate  VPA-­GFLG-­iRGD.  As  GFLG-­iRGD   is   toxic   to  DU-­145   prostate   cancer  
cells  at  the  tested  concentrations,  other  more  potent  drugs  should  be  chosen  to  prepare  the  
iRGD-­drug   conjugate   in   order   to   minimize   the   cytotoxicity   of   iRGD.   In   addition,  
experiments  are  needed  to  explain  the  cytotoxicity  of  GFLG-­iRGD.   
 In Chapter 4, we describe the design, preparation, and biological properties of 
stimuli-responsive HPMA copolymer drug and tumor-penetrating peptide conjugates. 
Doxorubicin (DOX) was conjugated to HPMA copolymer via a lysosomally cleavable 
tetrapeptide spacer (-GFLG-). Tumor homing and penetrating peptide iRGD was 
connected to HPMA copolymer through a MMP-2 degradable linker (-PLGLAG-). Free 
iRGD and monomer MA-GG-PLGLAG-iRGD were prepared with solid phase synthesis. 
HPMA copolymer-DOX conjugates (P-DOX and P-DOX-PLGLAG-iRGD) were 
prepared via conventional radical copolymerization. The uptake of DOX conjugates was 
tested in both monolayer and multilayer DU-145 prostate cancer cells with flow 
cytometry. The results have shown that P-DOX-PLGLAG-iRGD treated cells had the 
strongest fluorescence intensity compared to that of other treated groups (Control, iRGD, 
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P-DOX, P-DOX plus iRGD). The cell cycle arrest, in vitro apoptosis, and cytotoxicity of 
DOX conjugates and related controls were tested against DU-145 monolayer prostate 
cancer cells. Consistent with the drug uptake results, the in vitro activity results show that 
P-DOX-PLGLAG-iRGD had the strongest activity against DU-145 prostate cancer cells. 
The penetration ability of DOX conjugates was tested in 3D multicellular tumor cell 
spheroids. The results show that the conjugate P-DOX-PLGLAG-iRGD penetrated 
deepest in tumor cell spheroids.  
 The conjugation of iRGD to HPMA copolymer DOX conjugate via a MMP-2 
cleavable spacer increased the accumulation of DOX conjugates in mono- and multi-
layer DU-145 prostate cancer cells. More in vivo experiments including a bio-distribution 
and efficacy study should add to further prove the advantages of conjugation of iRGD to 
HPMA copolymer drug conjugates. To demonstrate the importance of a cleavable spacer 
between iRGD and drug carriers, one more control conjugate that links the iRGD to 
HPMA copolymer drug conjugate via a nondegradable spacer should be prepared and 
tested. As integrin is also expressed on tumor vascular endothelial cells, iRGD will likely 
interact with tumor vascular endothelial cells. As the conjugation of iRGD to HPMA 
copolymer DOX conjugate enhanced the accumulation in prostate cancer cells, its 
accumulation in tumor vascular endothelial cells should also be examined to determine if 
a similar effect can be observed. 
 In Chapter 5, a HPMA copolymer CXCR-4 antagonist (BKT140) conjugate was 
designed, synthesized, characterized, and its activities were tested against PC-3 prostate 
cancer cells. BKT140 was attached to HPMA backbone via a matrix metallopeptidase 2 
(MMP-2) cleavable spacer (-PLGLAG-). Both free BKT140 and monomer MA-GG-
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PLGLAG-BKT140 were prepared by solid phase synthesis. Fmoc-D-Lys(Dde)-OH and 
Fmoc-L-Lys(Boc)-OH were chosen for the synthesis of the monomer MA-GG-
PLGLAG-BKT140 in order to make sure the reaction selectively occurred at D-Lys8 
rather than L-Lys7. HPMA copolymer-BKT140 conjugate (P-PLGLAG-BKT140) was 
prepared via Reversible Addition-Fragmentation Chain Transfer copolymerization of 
monomer HPMA and MA-GG-PLGLAG-BKT140. The -PLGLAG- spacer was cleaved 
in prostate cancer cells growth media at a minimum of two sites. The in vitro cell 
cytotoxicity results showed that the free BKT140 and P-PLGLAG-BKT140 had the same 
activities against PC-3 cells, indicating that the conjugation of BKT140 to HPMA did not 
impact the functionality of BKT140. The migration results showed that both HPMA 
copolymer BKT140 conjugate and free BKT140 inhibited the CXCL12 induced PC-3 
prostate cancer cell migration. The conjugate P-PLGLAG-BKT140 had great impact than 
that of free BKT140. 
 Our present results showed that the conjugation of BKT140 to HPMA copolymer 
enhanced its ability to inhibit the CXCL12 induced prostate cancer migration. However, 
more experiments are required to demonstrate the mechanism of BKT140 conjugate. For 
example, what is the conformation of BKT140 in the conjugate? What is the morphology 
of HPMA copolymer BKT140 conjugate? How does the conjugate interact with CXCR4 
receptor on the tumor cell surface? In addition, further optimization of the structure of 
BKT140 conjugate is necessary to maximize the inhibition effect of BKT140. Other 
structures such as the star, dendrimer shape of BKT140 conjugates deserve to be prepared 
and tested. More HPMA copolymer BKT40 conjugates with different molecular weight 
and/or varied BKT140 distribution in the polymer chain should be prepared and assessed. 
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Furthermore, the ultimate goal of this part study is to develop new therapeutics for 
inhibiting prostate cancer metastasis. Cancer metastasis is a multistage process including 
invasion from the extracellular matrix and adherence to bone marrow endothelial cells. 
Whether the HPMA copolymer BKT140 conjugate can inhibit the invasion and 
adherence of prostate cancer cells should also be examined.  
  
 
 
 
  
